

# UBA6 specificity for ubiquitin E2 conjugating enzymes reveals a priority mechanism of BIRC6

Received: 7 April 2025

Accepted: 22 October 2025

Published online: 5 December 2025

 Check for updatesCarlos Riechmann<sup>1</sup>, Cara J. Ellison<sup>1</sup>, Jake W. Anderson<sup>1</sup>, Kay Hofmann<sup>2</sup>, Peter Sarkies<sup>1</sup> & Paul R. Elliott<sup>1</sup>✉

In mammals, ubiquitylation is orchestrated by the canonical ubiquitin-activating E1 enzyme UBA1 and the orthogonal E1 UBA6. Growing evidence underscores the essentiality of both E1s, which differentiate between 29 active ubiquitin-conjugating enzymes (E2s). The mechanisms governing this distinction have remained unclear. Here we establish a framework for ubiquitin E1–E2 specificity. Focusing on UBA6-controlled ubiquitylation cascades, we reveal that BIRC6, a UBA6-exclusive E2, gains priority over all other UBA6-competent E2s, underpinning the functional importance of defined UBA6–BIRC6 ubiquitylation events in regulating cell death, embryogenesis and autophagy. By capturing BIRC6 receiving ubiquitin from UBA6 in different states, we observe BIRC6 engaging with the UBA6 ubiquitin fold domain, driving an exceptionally high-affinity interaction that is modulated by the UBA6 Cys-Cap loop. Using this interaction as a template, we demonstrate how to confer activity between E2s and their noncognate E1, providing a tool to delineate E1–E2-dependent pathways. Lastly, we explain how BIRC6 priority does not lead to inhibition of UBA6, through a bespoke thioester switch mechanism that disengages BIRC6 upon receiving ubiquitin. Our findings propose a concept of hierarchy of E2 activity with cognate E1s, which may explain how ubiquitin E1s can each function with over a dozen E2s and orchestrate E2-specific cellular functions.

Most eukaryotic cellular processes are regulated by the post-translational attachment of ubiquitin and ubiquitin-like (UBL) proteins onto substrates<sup>1,2</sup>. Ubiquitin is highly conserved from yeast to humans and is covalently linked onto substrates through the cyclical activity of E1 ubiquitin-activating, E2 ubiquitin-conjugating and E3 ubiquitin ligases, ultimately forming defined monoubiquitin and polyubiquitin attachments with diverse consequences in substrate fate<sup>3,4</sup>.


Metazoans contain two E1 ubiquitin-activating enzymes, UBA1 (refs. 5–7) and UBA6 (refs. 8–10). UBA1 facilitates the majority of ubiquitylation events in the cell and is expressed at tenfold higher levels than UBA6 (ref. 8). However, UBA6 is expressed in all tissues<sup>8</sup> and both E1s are essential for development<sup>9</sup>, suggesting that UBA6 regulates

distinct, fundamental cellular pathways. These distinct functions of the two E1 enzymes are further underscored by different abnormalities arising upon perturbation of enzymatic activity. Somatic mutations in *UBA1* lead to VEXAS syndrome<sup>11,12</sup> while UBA6 has been implicated in neuronal functions, with brain specific *UBA6*-knockout mice displaying neurological disorders<sup>13,14</sup> and elevated UBA6 levels detected in Alzheimer's Disease patients<sup>15</sup>. Additionally, UBA6-mediated ubiquitylation events are exploited for survival of certain cancer cell lines across a broad range of tissues<sup>16</sup>.

Despite different cellular pathways being governed by UBA6, the E1 enzymes are homologous, share a conserved multidomain architecture (Fig. 1a, Extended Data Fig. 1a and Supplementary Fig. 1a)

<sup>1</sup>Department of Biochemistry, University of Oxford, Oxford, UK. <sup>2</sup>Institute for Genetics, University of Cologne, Cologne, Germany.

✉e-mail: [paul.elliott@bioch.ox.ac.uk](mailto:paul.elliott@bioch.ox.ac.uk)



**Fig. 1 | Overview of E1 specificity and E2-interacting domain compatibility**

**across the ubiquitin E2 family. a**, Left, sequence identity between domains of the ubiquitin-activating E1 enzymes UBA1 and UBA6. Right, schematic of the ubiquitin cascade. E1 enzymes sequentially activate two ubiquitin molecules (i–iii) before transthiolation to an E2 enzyme (iv), which then conjugates ubiquitin onto a substrate protein through an E3 enzyme (v). Numbers of ubiquitin E2 and E3 enzymes present in humans are indicated in brackets. **b**, Phylogenetic tree (ClustalOmega) of the 29 active ubiquitin E2 enzymes present in humans. **c**, Top, quantification of the percentage of E2-Ub thioester formed (mean  $\pm$  s.d.) for every human E2 enzyme after 5 min in the presence of UBA1/UBA6 in three independent experiments. Because of lower transthiolation activity, reactions with UBE2K were stopped after 30 min rather than 5 min.

**Asterisk denotes use of truncated E2.** Bottom, the Spearman rank correlation coefficient is shown for the expression of each enzyme across tissues in the GTEx database to either UBA1 or UBA6. Correlations that were not significant ( $P > 0.01$ ) after multiple-test correction are shown as **0**. **d**, Left, summary of E1 specificity among the panel of human E2s, determined from **c**. Right, classification of E1 domain specificity across all ubiquitin E2 enzymes, determined by observing E2-Ub thioester formation with chimeric UBA1/UBA6 constructs (Extended Data Fig. 1c, d). **e**, Codependency analysis correlating UBA6 CRISPR Chronos score with CRISPR Chronos score of  $-18,000$  genes across 1,186 cell lines in the cancer dependency map (DepMap). Pearson correlation coefficients for each gene pair are ranked by significance. Genes with Pearson correlation coefficients between  $-0.1$  and  $0.1$  are omitted for clarity.

and transfer ubiquitin to E2 conjugating enzymes through the same reaction cycle (Fig. 1a). Given these similarities, how can independent E1 pathways be achieved? Within this cycle, recruitment of E2s to the E1 is the key step in dividing the ubiquitin signal into distinct UBA1/UBA6-mediated pathways and offers an early opportunity for regulating downstream signaling. For example, UBA6 functions in

epithelial cell morphogenesis<sup>17</sup>, the integrated stress response<sup>16</sup> and autophagy<sup>18,19</sup>, the latter two through the giant E2/E3 BIRC6 recently identified as only the second UBA6-specific E2 (refs. 18,20–22).

While most other UBL systems are limited to two E2 enzymes, the ubiquitin system uses 29 (Fig. 1a)<sup>23</sup>. Consequently, the specificity-determining features on UBA1 and UBA6 are uniquely constrained,

as they must be subtle enough to accommodate dual active E2s while remaining sufficiently different to allow specificity. E1s in UBL cascades have been shown to exploit distinct features in both the ubiquitin fold domain (UFD)<sup>24–28</sup> and the second catalytic cysteine half (SCCH) domain<sup>29</sup> to impart specificity to the recruitment step. However, the molecular mechanisms governing parallel ubiquitin E1–E2 pathways within the ubiquitin cascade itself is not well understood<sup>8,17</sup>.

Through determining E1 specificity drivers for the human ubiquitin E2 family, we uncover a hierarchy of E2s for UBA6 activity, placing BIRC6 with overall priority. By capturing both ubiquitin-free and ubiquitin-transfer UBA6–BIRC6 states, we identify the mechanism underpinning ubiquitin transfer to BIRC6, thus explaining how BIRC6 specificity and priority for UBA6 are achieved without inhibiting UBA6.

## Results

### Differential E1–E2 recruitment is governed by UFD and SCCH domains

We established a reactivity profile of all active 29 ubiquitin-conjugating E2s against UBA1 or UBA6 by quantifying E2–Ub thioester formation for recombinantly purified E2 enzymes (Fig. 1b–d and Extended Data Fig. 1b). A total of 14 E2s were specific to UBA1, two were specific to UBA6 and 13 were dual-reactive toward UBA1 and UBA6 (Fig. 1d). Strikingly, E1 specificity did not track with E2 homology; even E2s within the same family (UBE2J1/J2, 32.8% sequence identity; UBE2G1/G2, 49.7% sequence identity) displayed different E1 specificities (Fig. 1c), demonstrating that subtle differences have evolved within E2s that dramatically affect E1 specificity.

To determine which domains within UBA1/UBA6 drive E2 specificity, we extended our reactivity profile to include chimeric E1s with either the UFD or the SCCH domain swapped (Fig. 1d and Extended Data Fig. 1c, d). Previous analysis focused on specific E1–E2 pairs in the ubiquitin system<sup>8</sup> and parallel UBL systems<sup>24,28,30</sup>. By including the entire ubiquitin E2 family, we show that, of the 14 UBA1-specific E2 enzymes, eight were driven by UFD alone while the remaining six required both the UBA1 UFD and the UBA1 SCCH domains. Interestingly, the two UBA6-specific E2s use distinct mechanisms to achieve selectivity for UBA6. UBE2Z was driven by the SCCH alone, while combined interactions with UFD and SCCH were required for BIRC6 activity (full-length BIRC6 and the BIRC6 UBC domain, amino acids 4498–4820 (BIRC6<sup>UBC</sup>); Extended Data Fig. 1d).

E2 specificities *in vitro* were mirrored in correlations between E2s and UBA1 and UBA6 in healthy tissue, derived from the analysis of RNAseq data from the GTex portal (<https://www.gtexportal.org/home/>) (Fig. 1c, bottom). Notably, UBE2Z and BIRC6, which showed the highest specificity for UBA6, clustered together with UBA6 and away from UBA1 in a correlation matrix (Extended Data Fig. 1e, f). In addition to a gene expression link between UBA6 and its specific E2s, a functional correlation was also evident; codependency analysis in cancer cell lines from the DepMap database (<https://depmap.org/portal/>)<sup>31</sup> revealed that *BIRC6* is the strongest codependent gene for *UBA6* (Pearson correlation 0.7) and is significantly more dependent than the next highest codependent E2 *UBE2Z* with a Pearson correlation of 0.2 (Fig. 1e), suggesting a strong cellular requirement for UBA6 function with BIRC6.

### BIRC6 gains priority to UBA6 over other E2s

The strong functional link between UBA6 and BIRC6 led us to investigate their biochemical relationship. We previously detected UBA6 as a top cellular interaction partner of BIRC6 by mass spectrometry analysis<sup>20</sup>. Here, we used analytical size-exclusion chromatography (SEC) to determine whether this is the result of a direct interaction between the two enzymes. Indeed, in contrast to previously studied E1–E2 interactions in the ubiquitin cascade<sup>5,32</sup>, BIRC6<sup>UBC</sup> forms a stable complex with UBA6 without the addition of ubiquitin or ATP (Fig. 2a). BIRC6<sup>UBC</sup> does not coelute with UBA1 (Supplementary Fig. 2a), highlighting that the


E1–BIRC6 stable interaction only occurs with its cognate E1. Neither UBE2Z nor the cross-reactive E2 UBE2D2 formed stable complexes with UBA6 (Supplementary Fig. 2b, c) revealing that stable complex formation in the absence of ubiquitin and ATP is not a requirement for UBA6 reactivity; instead, it is specific to BIRC6.

To uncover the molecular features governing the strong association between BIRC6<sup>UBC</sup> and UBA6, we determined the cryo-electron microscopy (cryo-EM) structure of UBA6 in complex with the BIRC6 UBC domain (Fig. 2b–d, Extended Data Figs. 2a–d and 3a–c and Table 1). UBA6 particles could be classified into three states, from which maps of 3.3–3.6-Å resolution were reconstructed: UBA6<sup>APO</sup> (Extended Data Fig. 2a), with no BIRC6<sup>UBC</sup> bound, and two distinct BIRC6-bound conformations. In one conformation (UBA6–BIRC6<sup>UBC-OUT</sup>), BIRC6<sup>UBC</sup> associates with the UBA6 UFD and rests over a loop obscuring the E1 catalytic Cys, previously described as the Cys-Cap loop (Fig. 2b; buried surface area with UFD: 900 Å<sup>2</sup>, buried surface area with Cys-Cap loop: 210 Å<sup>2</sup>). In the second conformation (UBA6–BIRC6<sup>UBC-IN</sup>), BIRC6<sup>UBC</sup> is fully engaged with both the UFD and the SCCH domain (Fig. 2c; buried surface area with UFD: 770 Å<sup>2</sup>, buried surface area with SCCH: 600 Å<sup>2</sup>) and both UBA6 and BIRC6<sup>UBC</sup> are positioned similarly to all previously solved E1–E2 structures<sup>25–27,33–36</sup>. Notably, BIRC6<sup>UBC</sup> maintains a similar interface with the UBA6 UFD in both UBA6–BIRC6<sup>UBC-OUT</sup> and UBA6–BIRC6<sup>UBC-IN</sup> states (Fig. 2d and Extended Data Fig. 3d), requiring a 16° rotation of the UFD.

Three-dimensional variability analysis (3DVA) of the UBA6<sup>APO</sup> and UBA6–BIRC6<sup>UBC-OUT</sup> particle stacks revealed notable conformational heterogeneity (Extended Data Fig. 3b), which could be attributed to distinct domain movements. In UBA6<sup>APO</sup>, simultaneous rotations of the UFD (14°) and SCCH (6°) domains modulate the width of the central E2-binding cavity, highlighting the inherent structural plasticity of UBA6 to accommodate a range of E2 enzymes (Extended Data Fig. 3e). In the UBA6–BIRC6<sup>UBC-OUT</sup> state, concerted motion of both the UBA6 UFD and bound BIRC6<sup>UBC</sup> was visible, in which a 9° lateral rotation of the UBA6 UFD accompanies a 16-Å shift of BIRC6<sup>UBC</sup> while maintaining an identical interface with UBA6<sup>UFD</sup> (Extended Data Fig. 3f, g).

Given the consistency of BIRC6<sup>UBC</sup> interactions with UBA6<sup>UFD</sup> in all observed states, we reasoned that the BIRC6<sup>UBC</sup>–UFD interaction was the driver for the stable complex formation observed in analytical SEC. In agreement with this, isothermal titration calorimetry (ITC) measurements using isolated UBA6<sup>UFD</sup> and BIRC6<sup>UBC</sup> confirmed low-micromolar binding ( $K_d$ : 1.8 ± 0.5 μM) (Fig. 2f). Using a fluorescence polarization binding assay, we detected increased affinity between BIRC6<sup>UBC</sup> and full-length UBA6 ( $K_d$ : 200 ± 58 nM) mediated by additional contacts to the SCCH domain (Fig. 2g). Consistent with our analytical SEC analysis (Supplementary Fig. 2c), no binding was detected between full-length UBA6 and UBE2Z (Fig. 2g).

We next investigated functional consequences of the high-affinity UBA6–BIRC6<sup>UBC</sup> interaction and asked whether this manifests in BIRC6<sup>UBC</sup> priority over other UBA6-active E2s. To investigate this, we examined E2 loading in transthiolation reactions limited to a single turnover of UBA6 activity. Strikingly, we observed preferential ubiquitin transfer to full-length BIRC6 and BIRC6<sup>UBC</sup> over UBE2D2, whereas ubiquitin was transferred equally between UBE2Z and UBE2D2 (Fig. 2h and Extended Data Fig. 4a, b). Expanding this further, we found that catalytically inactive BIRC6<sup>UBC</sup> (BIRC6<sup>UBC</sup>-C4666A) outcompeted all other UBA6-active E2s (Extended Data Fig. 4c), demonstrating BIRC6 as the priority E2 for UBA6. To verify that the strong binding ability of BIRC6<sup>UBC</sup> is required for priority, we generated a structure-guided BIRC6<sup>UBC</sup> mutant that partially disrupts the interaction with UBA6<sup>UFD</sup> whilst remaining transthiolation competent (Fig. 2e). To this effect, the BIRC6<sup>UBC</sup>-A4575D mutant prevented binding to UBA6<sup>UFD</sup> by ITC (Fig. 2f) and full-length UBA6 according to fluorescence polarization (Fig. 2g), with only a modest reduction in thioester formation (Extended Data Fig. 4d), confirming the suitability of this mutant to delineate the contribution of E1 binding for BIRC6 priority. Crucially, BIRC6<sup>UBC</sup>-A4575D was unable



**Fig. 2 | A strong interaction between BIRC6<sup>UBC</sup> and UBA6<sup>UFD</sup> results in transthiolation priority for BIRC6 over other E2 enzymes.** **a**, Analytical SEC of BIRC6<sup>UBC</sup> with UBA6 without the addition of ubiquitin or ATP. MW, molecular weight. **b, c**, Cryo-EM maps of two noncovalent BIRC6<sup>UBC</sup> binding modes with UBA6. The sample was obtained from an initial trial to form the trapped ternary complex between BIRC6, UBA6 and ubiquitin, outlined in Fig. 4c. **b**, BIRC6<sup>UBC</sup> bound at UBA6<sup>UFD</sup>, with the Cys-Cap loop ordered (UBA6–BIRC6<sup>UBC-OUT</sup>). **c**, BIRC6<sup>UBC</sup> engaged with UFD and SCCH domains, with the Cys-Cap loop displaced (UBA6–BIRC6<sup>UBC-IN</sup>). **d**, Comparison of the UBA6–BIRC6<sup>UBC-IN/OUT</sup> atomic models. A 16° rotation of the UBA6<sup>UFD</sup> is required to accommodate the UBA6 Cys-Cap loop. **e**, Close-up view of the BIRC6<sup>UBC</sup>–UBA6<sup>UFD</sup> interaction of

the UBA6–BIRC6<sup>UBC-IN</sup> model. **f**, ITC of UBA6<sup>UFD</sup> (residues 940–1052) binding to BIRC6<sup>UBC</sup> ( $K_d$ : 1.8  $\mu$ M  $\pm$  0.5  $\mu$ M) and BIRC6<sup>UBC</sup>-A4575D (no binding). **g**, Fluorescence polarization measurements of full-length UBA6 binding to Cy5-labeled BIRC6<sup>UBC</sup>, UBE2Z and BIRC6<sup>UBC</sup>-A4575D. Binding was detected for BIRC6<sup>UBC</sup>. FP, fluorescence polarization. Data shown are the mean  $\pm$  s.d. from experiments performed in technical triplicate. Binding affinities determined from two independent experiments. **h**, BDP-labeled ubiquitin single-turnover transthiolation reactions from UBA6 to UBE2D2, either alone or competing with a second E2 (BIRC6<sup>UBC</sup>, UBE2Z or BIRC6<sup>UBC</sup>-A4575D). Controls for E2-Ub thioester formation of BIRC6<sup>UBC</sup>, UBE2Z and BIRC6<sup>UBC</sup>-A4575D without UBE2D2 are included in Extended Data Fig. 4a. The gel is representative of three independent experiments.

to outcompete UBE2D2 from receiving ubiquitin from UBA6 (Fig. 2h), demonstrating that strong UFD binding bestows BIRC6 with priority for UBA6 activity ahead of other UBA6-competent E2s.

### BIRC6<sup>UBC</sup>–UBA6<sup>UFD</sup> interaction explains specificity for UBA1-specific E2s

Our UBA6–BIRC6<sup>UBC</sup> structures capture UBA6 bound to an E2 for the first time, enabling structural comparisons to UBA1-specific E2s to uncover their mechanisms of specificity. The interaction of E2 enzymes with their cognate E1 UFD is mostly mediated through an  $\alpha$ -helix (typically helix 1) of the E2 (refs. 27,37–39), with additional contributions from a nearby loop (typically loop 2) (Fig. 3a and Extended Data Fig. 4e).


In BIRC6<sup>UBC</sup>, this interface comprises a series of hydrophobic residues directed toward UBA6<sup>UFD</sup> (Fig. 2e). To complement this interaction, the E2-binding surface presented by the UBA6 UFD is more hydrophobic than that of UBA1 (ref. 8).

Superimposition of crystal structures of UBA1-specific E2s selected from our E2 panel (Fig. 1d) onto our BIRC6<sup>UBC-IN</sup> model revealed several unfavorable interactions from helix 1 of these E2s that would disrupt an interface with UBA6<sup>UFD</sup> (Fig. 3a,b). Focusing on the UBA1-specific E2s UBE2E1, UBE2H and UBE2W, we derived mutations within helix 1 centered on positions 3, 7 and 11 to remove steric clashes or charged side chains that may prevent favorable recruitment to UBA6 without impairing activity toward UBA1 (Fig. 3b). Indeed, substitutions of two or three

**Table 1 | Summary of data collection and model refinement parameters for structures generated from the UBA6–BIRC6<sup>UBC</sup> dataset**

	UBA6 <sup>APO</sup> Consensus	UBA6 <sup>APO</sup> Cluster 2	UBA6 <sup>APO</sup> Cluster 3	UBA6–BIRC6 <sup>UBC-IN</sup>	UBA6–BIRC6 <sup>UBC-OUT</sup> Consensus	UBA6–BIRC6 <sup>UBC-OUT</sup> Cluster 0	UBA6–BIRC6 <sup>UBC-OUT</sup> Cluster 4
	EMD-53184	EMD-53187	EMD-53188	EMD-53195	EMD-53190	EMD-53192	EMD-53193
	PDB 9QIC	PDB 9QIG	PDB 9QII	PDB 9QIV	PDB 9QIM	PDB 9QIO	PDB 9QIP
<b>Data collection and processing</b>							
Microscope	Krios (eBIC)	Krios (eBIC)	Krios (eBIC)	Krios (eBIC)	Krios (eBIC)	Krios (eBIC)	Krios (eBIC)
Magnification	×105,000	×105,000	×105,000	×105,000	×105,000	×105,000	×105,000
Voltage (kV)	300	300	300	300	300	300	300
Detector	K3 BioQuantum	K3 BioQuantum	K3 BioQuantum	K3 BioQuantum	K3 BioQuantum	K3 BioQuantum	K3 BioQuantum
Slit width (eV)	20	20	20	20	20	20	20
Electron exposure (e <sup>-</sup> per Å <sup>2</sup> )	37.45	37.45	37.45	37.45	37.45	37.45	37.45
Defocus range (μm)	−0.5, −2.5	−0.5, −2.5	−0.5, −2.5	−0.5, −2.5	−0.5, −2.5	−0.5, −2.5	−0.5, −2.5
Pixel size (Å)	0.825	0.825	0.825	0.825	0.825	0.825	0.825
Symmetry imposed	C <sub>1</sub>	C <sub>1</sub>	C <sub>1</sub>	C <sub>1</sub>	C <sub>1</sub>	C <sub>1</sub>	C <sub>1</sub>
Micrographs (no.)	13,511	13,511	13,511	13,511	13,511	13,511	13,511
Picking software	crYOLO	crYOLO	crYOLO	crYOLO	crYOLO	crYOLO	crYOLO
Initial particle images (no.)	2,210,743	2,210,743	2,210,743	2,210,743	2,210,743	2,210,743	2,210,743
Final particle images (no.)	253,166	19,111	17,392	136,457	139,520	10,415	9,889
Map resolution (Å)	3.29	3.94	3.99	3.44	3.57	4.22	4.15
FSC threshold	0.143	0.143	0.143	0.143	0.143	0.143	0.143
Map resolution range: 25th, 75th percentile (Å)	3.32, 6.91	5.19, 8.12	5.33, 8.13	3.42, 7.42	3.91, 7.66	5.94, 9.40	5.66, 9.28
<b>Refinement</b>							
Initial model used (PDB code)	AlphaFold prediction	AlphaFold prediction	AlphaFold prediction	AlphaFold prediction	AlphaFold prediction	AlphaFold prediction	AlphaFold prediction
Model resolution (Å)	3.4	4.1	4.2	3.6	3.7	4.6	4.5
FSC <sup>1</sup> threshold	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Model resolution range: 25th, 75th percentile (Å)	3.32, 6.91	5.19, 8.12	5.33, 8.13	3.42, 7.42	3.91, 7.66	5.94, 9.40	5.66, 9.28
Map sharpening B factor (Å <sup>2</sup> )	165.5	125.3	122.9	147.6	155.3	122.7	119.9
<b>Model composition</b>							
Nonhydrogen atoms	8,077	8,077	8,077	10,258	10,433	10,433	10,433
Protein residues	1,011	1,011	1,011	1,282	1,305	1,035	1,035
Ligands	2	2	2	2	2	2	2
<b>B factors (Å<sup>2</sup>)</b>							
Protein	168.79	223.60	208.95	141.14	191.60	265.36	261.75
Ligand	169.33	218.25	222.04	156.04	177.03	254.87	257.75
<b>R.m.s.d.</b>							
Bond lengths (Å)	0.003	0.004	0.005	0.002	0.002	0.002	0.002
Bond angles (°)	0.455	0.685	0.702	0.443	0.438	0.586	0.595
<b>Validation</b>							
MolProbity score	1.14	1.62	1.82	1.25	1.15	1.36	1.36
Clashscore	3.54	9.31	13.79	4.85	3.56	6.55	6.46
Poor rotamers (%)	0.45	0.45	0.78	0.79	0.26	0.00	0.00
<b>Ramachandran plot</b>							
Favored (%)	98.61	97.32	97.03	98.51	99.00	98.16	98.62
Allowed (%)	1.39	2.68	2.97	1.49	1.00	1.84	1.38
Disallowed (%)	0.00	0.00	0.00	0.00	0.00	0.00	0.00

<sup>1</sup>FSC, Fourier shell correlation.



**Fig. 3 | Modulating E2 specificity through site-directed mutagenesis and domain truncations.** **a**, Comparison of E1<sup>UFD</sup>-interacting helix (helix 1) sequences from UBA1-specific E2s and the UBA6-specific E2 BIRC6. Annotated residues (3, 7 and 11) face toward E1<sup>UFD</sup> during E1–E2 binding. Residues are colored on the basis of their properties defined by the Clustal coloring scheme. **b**, Unfavorable interactions of the UBA1-specific E2s UBE2H (PDB 8PJJN (ref. 65), green) and UBE2W (PDB 8A58 (ref. 66), blue) when modeled into UBA6<sup>UFD</sup>. **c**, Quantification of E2-Ub thioester formation (mean  $\pm$  s.d.) for WT and mutant UBA1-specific E2s with UBA1/UBA6 from three independent experiments (additional BDP-labeled gel image in Extended Data Fig. 4f). **d**, Favorable interaction of UBE2D2

(PDB 2ESK (ref. 67), slate) when modeled into UBA6<sup>UFD</sup>. **e**, Quantification of E2-Ub thioester formation (mean  $\pm$  s.d.) for WT and mutant UBE2D2 with UBA1/UBA6 from three independent experiments (additional BDP-labeled gel image in Extended Data Fig. 4g). NS, not significant. **f**, Top, domain architecture of the UBE2Q family proteins; regions labeled N/C were truncated in the  $\Delta$ N/ $\Delta$ C constructs, respectively. Bottom, quantification of E2-Ub thioester formation (mean  $\pm$  s.d.) for WT and truncated UBE2Q constructs from three independent experiments (additional BDP-labeled gel image in Extended Data Fig. 4h). Significance levels from unpaired *t*-tests of all quantification comparisons (**c**,**e**,**f**): \**P* < 0.05, \*\**P* < 0.01 and \*\*\**P* < 0.001.

amino acids from helix 1 were sufficient to confer activity with UBA6 without severely compromising UBA1 activity (Fig. 3c and Extended Data Fig. 4f). Conversely, addition of negatively charged residues at the UBA6<sup>UFD</sup> interface of the cross-reactive E2 UBE2D2 (Fig. 3d) specifically hindered UBA6 transthiolation activity while retaining UBA1 activity (Fig. 3e and Extended Data Fig. 4g). Together, this mutational analysis shows that our BIRC6–UBA6 structural analyses offer a template for modulating the activity of other E2s for noncognate E1s. Importantly, these derived mutations do not overlap with known interfaces with E3 ligases, confirmed by comparison to E2–E3 structures (Extended Data Fig. 4i–p), demonstrating the applicability of this approach to specifically alter the E1–E2 step of E2-regulated cellular processes.


In addition to the canonical helix 1/loop 2 E1-interacting interface, many E2 UBC domains possess N-terminal or C-terminal extensions (Supplementary Fig. 3) that regulate their activity<sup>40–44</sup> and, in the case of the Nedd8 E2 (Ubc12), interact with its cognate E1 UBA3 (ref. 45). We explored the contribution of UBC extensions for driving UBA1/UBA6 ubiquitin E2 specificity by focusing on the UBA1-specific UBE2Q family (Fig. 1d), which contain both an additional N-terminal domain and an extended C-terminal helix (Fig. 3f). UBA1<sup>UFD</sup> was required for transthiolation activity with full-length UBE2Q constructs (Extended Data Fig. 1d); however, successive truncation of the N-terminal and C-terminal extensions of both UBE2Q1 and UBE2Q2 revealed robust activity with UBA6 (Fig. 3f and Extended Data Fig. 4h), suggesting that steric occlusion by the UBC extensions masked favorable interactions

with UBA6. This demonstrates for the first time that extensions to the UBC of ubiquitin E2s can determine E1 specificity.

### *Drosophila melanogaster* harbors an E1-bispecific BIRC6 ortholog

Although BIRC6<sup>UBC</sup> binds tightly to UBA6<sup>UFD</sup> (Fig. 2f,g), this interaction does not fully explain the specificity of BIRC6 for UBA6, as BIRC6 was dependent on both UFD and SCCH domains for full activity (Extended Data Fig. 1d). To better understand the origins of UBA6-specificity in BIRC6, we took an evolution-guided approach and observed that, while BIRC6 is conserved in all metazoans, UBA6 has been lost in Nematoda and Arthropoda including *Drosophila* (Fig. 4a). Despite this, BIRC6 has established roles in *Drosophila* cell death and development pathways, which require catalytic activity<sup>46,47</sup>.

Recent cryo-EM structures of full-length human BIRC6 revealed a highly interwoven architecture of multiple domains N-terminal to the catalytic UBC domain<sup>20–22,48</sup>. *D. melanogaster* BIRC6 (dBIRC6) is 53% identical to human BIRC6, with all domains conserved across the ~5,000-amino acid protein<sup>20</sup>. The dBIRC6 catalytic domain (dBIRC6<sup>UBC</sup>) displays even higher conservation, with 69% sequence identity to human BIRC6<sup>UBC</sup>. The *D. melanogaster* genome contains a single E1 dedicated to the activation of ubiquitin (dUBA1), which has 60% sequence identity to human UBA1 and is only 42% identical to UBA6. Given the functional importance of dBIRC6 but absence of UBA6 in *Drosophila*, we reasoned that dBIRC6 must have functionally coevolved



**Fig. 4 | Structures of trapped UBA6-UbDha-BIRC6<sup>UBC</sup> and dUBA1-UbDha-dBIRC6<sup>UBC</sup> ternary complexes reveal E1 specificity determinants of BIRC6.** **a**, Phylogenetic analysis of BIRC6 and UBA6 conservation. Ticks and crosses indicate the presence or absence of BIRC6 and UBA6 in the indicated taxa. **b**, E2-Ub transthiolation assay for human and *Drosophila* BIRC6<sup>UBC</sup> with the two human E1 enzymes (UBA1 and UBA6) and the *Drosophila* E1 (dUBA1). Left, SDS-PAGE gel used for quantification. Right, quantification of the percentage of E2-Ub formation (mean  $\pm$  s.d.) from three independent replicates. **c**, Chemical structures of the transient E1-Ub-E2 tetrahedral intermediate (left) and the trapped ternary complex formed by the UbDha probe (right). **d, e**, Consensus cryo-EM densities for UBA6-UbDha-BIRC6<sup>UBC</sup> (**d**) and dUBA1-UbDha-dBIRC6<sup>UBC</sup> (**e**)

(**e**) trapped ternary complexes. Density for Ub<sup>Tran</sup> is lost because of heterogeneity in Ub<sup>Tran</sup> conformations within the consensus particle stacks. **f**, Close-up view of the E1-UbDha-E2 bridge between catalytic residues within the UBA6-UbDha-BIRC6<sup>UBC</sup> structure. **g**, 3DVA and clustering of the UBA6-UbDha-BIRC6<sup>UBC</sup> particle stack recover density for transferred ubiquitin. **h**, Top, schematic of WT (human/*Drosophila*, h/d) and chimeric (1-10) BIRC6<sup>UBC</sup> constructs. Bottom, SDS-PAGE gel showing E2-Ub thioester formation of chimeric BIRC6 constructs in the presence of either UBA1 or UBA6 using BDP-labeled ubiquitin. The gel is representative of three independent experiments. **i**, Close-up view of the UFD-BIRC6<sup>UBC</sup> interface. Helices extended in dUBA1<sup>UFD</sup> compared to UBA6 are outlined.

to receive ubiquitin from dUBA1. We confirmed this functional partnership in transthiolation assays (Fig. 4b). Remarkably, unlike BIRC6<sup>UBC</sup>, dBIRC6<sup>UBC</sup> displayed species cross-reactivity with both human UBA1 and UBA6 (Fig. 4b), suggesting that, despite the high sequence identity between the human and *Drosophila* orthologs, features within dBIRC6<sup>UBC</sup> allow E1 bispecificity. Armed with the understanding of dBIRC6's cross-species E1 reactivity, we aimed to leverage it as an effective tool for exploring E1 specificity.

### Capturing BIRC6<sup>UBC</sup> orthologs receiving ubiquitin from species-specific E1s

To understand the species-specific differences within BIRC6 UBC domains enabling E1 specificity, we sought to capture human and

*Drosophila* BIRC6<sup>UBC</sup> orthologs bound to their respective E1 enzymes. Unlike human BIRC6, dBIRC6<sup>UBC</sup> is unable to form a stable complex with either *Drosophila* or human E1 enzymes (Extended Data Fig. 5a-c); therefore, a strategy to stabilize the dBIRC6 complex was required. Previous methods to obtain stable E1-E2 complexes for structural studies have involved oxidative crosslinking between the catalytic cysteine residues of E1 and E2 (refs. 25-27,34,35). To stabilize our E1-BIRC6<sup>UBC</sup> complex, we capitalized on the observation that a ubiquitin dehydroalanine probe (UbDha) can be reacted with an E1 and transferred to an E2, forming a trapped ternary complex that closely resembles the native transthiolation tetrahedral intermediate<sup>49</sup> (Fig. 4c and Extended Data Fig. 5d-f). Recently, a transthiolation-mimic state was also captured through use of a ubiquitin-PSAN probe<sup>36</sup>. Using probes to trap

transthiolation-mimic states allows for the stabilization of transient E1–E2 interactions while preserving the native conformations of the enzymes involved.

Using the UbDha strategy, we determined cryo-EM maps of dUBA1–UbDha–dBIRC6<sup>UBC</sup> and UBA6–UbDha–BIRC6<sup>UBC</sup> at overall resolutions of 2.6 and 3.1 Å, respectively (Fig. 4d,e, Extended Data Figs. 6–8 and Table 2). Unambiguous maps enabled building of the E1–E2 complexes in both single and double ubiquitin-loaded states, as also observed in recent cryo-EM structures of yeast UBA1–Cdc34 (ref. 36). The C-terminal tail of UbDha midtransfer from E1 to BIRC6 could be resolved in both maps, enabling confident modeling of the covalent bonds between UbDha and the active sites of the respective E1 and BIRC6<sup>UBC</sup> (Fig. 4f and Extended Data Fig. 9a). Although the final residues of the UbDha tail were clearly resolved, the remainder of the transferred ubiquitin (Ub<sup>Tran</sup>) was only visible at lower map thresholds, indicative of conformational heterogeneity. Analysis of our structures revealed that Ub<sup>Tran</sup> adopts a continuum of conformations, which was correlated with progression through the transthiolation reaction in previous studies<sup>35,36</sup>. By clustering our particles into subsets using 3DVA, we were able to improve resolution for the Ub<sup>Tran</sup> (Fig. 4g and Extended Data Figs. 8b and 9b). We then validated the functional importance of the observed interfaces of BIRC6<sup>UBC</sup> to UBA6<sup>UFD</sup>, UBA6<sup>SCCH</sup> and Ub<sup>Tran</sup> (Extended Data Fig. 9c,d) and, consistent with our structural observations, single-point mutations in BIRC6<sup>UBC</sup> disrupt transthiolation. Conversely, the M992E substitution within UBA6<sup>UFD</sup> severely reduced loading of UBE2Z and UBE2D2 without significantly affecting BIRC6<sup>UBC</sup> loading (Extended Data Fig. 9e), suggesting that BIRC6 may tolerate mutations in UBA6 that would disrupt recruitment of weaker-binding E2s.

### Subtle differences within BIRC6<sup>UBC</sup> drive specificity for UBA6

Comparative analysis of the human and *Drosophila* E1–UbDha–BIRC6<sup>UBC</sup> complexes revealed that both UBC domains adopt similar conformations when bound to their cognate E1, with an overall root-mean-square deviation (r.m.s.d.) of 1.2 Å (Extended Data Fig. 10a); the largest differences occurred in poorly resolved loops. However, when aligned on the E1 core residues, subtle differences in the location of BIRC6<sup>UBC</sup> could be observed between the two structures. dBIRC6<sup>UBC</sup> pivots around its E1<sup>UFD</sup>-interacting helix, shifting the center of mass of BIRC6 2.1 Å away from E1<sup>SCCH</sup>, with local shifts of up to -5 Å in residues closer to the SCCH interface (Extended Data Fig. 10b,c). Next, we developed a series of BIRC6<sup>UBC</sup> species-swap chimeras that exchange human and *Drosophila* BIRC6 sequences to evaluate a hierarchy of interactions required for dBIRC6<sup>UBC</sup> bispecificity (Fig. 4h and Extended Data Fig. 10d,e). Adding C-terminal SCCH-interacting regions from BIRC6 into dBIRC6<sup>UBC</sup> retained partial activity with UBA1 (Fig. 4h, chimera 9). However, incorporating the N-terminal UFD-interacting region from BIRC6 into dBIRC6<sup>UBC</sup> eliminated ubiquitin loading from UBA1, regardless of other sequence alterations (Fig. 4h, chimeras 3, 7, 8 and 10, and Extended Data Fig. 10e). This underscores critical differences in how the two BIRC6<sup>UBC</sup> orthologs engage their respective cognate UFDs.

Focusing on the BIRC6<sup>UBC</sup>–UFD interface resolved in our structures, we observed clashes between BIRC6<sup>UBC</sup> and two helices in dUBA1<sup>UFD</sup> that are extended by one turn relative to UBA6 (Fig. 4i). These extra turns are also present in human UBA1 (Extended Data Fig. 10f). Upon close inspection of the BIRC6<sup>UBC</sup> domains, these clashes could be localized to two glutamic acid residues (E4603 and E4604). The corresponding residues in dBIRC6<sup>UBC</sup> are both shorter and, thus, compatible with the extended helices in both UBA1 orthologs. Incorporating the dBIRC6 N-terminal sequence up to and including helix 1 (residues 4577–4648 of dBIRC6) alone into BIRC6<sup>UBC</sup> did not elicit activity with UBA1 (Fig. 4h, chimera 1). However, further introduction of E4603T and E4604D substitutions into the sequence of this chimera began to enable UBA1 activity (Fig. 4h, chimera 2). This effect was also seen in chimeras containing the dBIRC6<sup>UBC</sup> C-terminal sequence (Fig. 4h, chimeras 4 and 5). Taken together, the N-terminal UFD-interacting region

of BIRC6<sup>UBC</sup> is key for driving E1 specificity for UBA6, with additional minor contributions from the SCCH interface.

### A bespoke thioester switch mechanism ensures BIRC6 priority occurs without UBA6 inhibition

The tight association of BIRC6<sup>UBC</sup> with UBA6 enables BIRC6 to take priority over other E2s for ubiquitin loading (Fig. 2h and Extended Data Fig. 4c) but risks BIRC6 acting as a competitive inhibitor of UBA6. As we observed robust ubiquitin transfer between UBA6 and BIRC6<sup>UBC</sup> indicating multiple turnovers of transthiolation, we reasoned that a mechanism must exist that ensures release of BIRC6–Ub.

First, we investigated what effect the presence of BIRC6<sup>UBC</sup> has on UBE2D2 loading under multiple-turnover conditions. BIRC6<sup>UBC</sup> suppresses UBE2D2 loading in a concentration-dependent manner and this competition markedly increases when catalytically inactive BIRC6<sup>UBC</sup>-C4666A is used (Fig. 5a,b). This suggests that ubiquitin transfer promotes BIRC6 release. Enhanced competition by BIRC6<sup>UBC</sup>-C4666A still requires a tight initial affinity to UBA6, as shown by the inability of UBE2Z-C4666A or UBE2Z-A4575D;C4666A to outcompete UBE2D2 (Fig. 5a,b and Supplementary Fig. 4a).

E2–Ub release mechanisms have been described as a thioester switch through reduced affinity of the E1–E2 complex after transthiolation has occurred<sup>33,50</sup>. Thus, we sought to directly measure the reduction in affinity of loaded BIRC6–Ub to UBA6. To assess this, we generated a stable Cy5–BIRC6–Ub conjugate using our UbDha strategy (Supplementary Fig. 5a). In fluorescence polarization measurements, BIRC6–Ub bound to UBA6 approximately 1.5-fold weaker ( $K_d$ : 273 nM ± 139 nM) than BIRC6 alone ( $K_d$ : 200 nM ± 58 nM) (Fig. 5c), indicating that, once BIRC6 has received ubiquitin, the product is of lower affinity and, thus, is released, consistent with a thioester switch.

The thioester switch mechanism may be driven by conformational changes that occur during ubiquitin transfer. Comparison of our unloaded and trapped transthiolation-mimic BIRC6<sup>UBC</sup> structures revealed a conformational change in the BIRC6 ‘loop 6’ extension (Fig. 5d; hereafter referred to as the blocking loop), which opens to accommodate the C-terminal tail of Ub<sup>Tran</sup> upon ubiquitin loading. Within this loop, a highly conserved tryptophan (W4673) occludes the active-site cysteine and must reposition for transthiolation to occur (Fig. 5e).

We generated three mutant BIRC6<sup>UBC</sup> blocking loop constructs and assessed their ability to outcompete UBE2D2 loading in a more sensitive time-course assay. Two focused on the conserved tryptophan residue, replacing it with either alanine, negating the need for a conformational change to unmask the E2 catalytic cysteine (W4673A), or arginine, which would alter the conformation of the blocking loop or surrounding regions (W4673R). The final mutant replaced the entire blocking loop (residues 4671–4680; Fig. 5f) with a short GG linker, effectively removing the loop entirely (BIRC6 Δblocking loop).

Removal of the blocking loop marginally enhanced BIRC6’s ability to outcompete UBE2D2 loading relative to wild-type (WT) BIRC6<sup>UBC</sup> and, furthermore, this was enhanced relative to thioester switch-impaired BIRC6<sup>UBC</sup> (C4666A) (Fig. 5g). The W4673A substitution showed slightly improved competition compared to WT BIRC6<sup>UBC</sup>, whereas W4673R showed a reduced ability to compete (Fig. 5g) but greater competition than BIRC6<sup>UBC</sup>-A4575D and UBE2Z (Fig. 5h). As the multiple-turnover competition assays are influenced by the E1–E2 affinity, we measured the affinities of the blocking loop variants to UBA6 to determine whether the observed competition effects correlate with an altered affinity. The W4673A mutant showed a slight increase in binding whilst W4673R was unable to bind, consistent with the competition assay results (Fig. 5i). Surprisingly, removal of the blocking loop weakened affinity to UBA6 compared to BIRC6<sup>UBC</sup> WT approximately twofold (Fig. 5i), despite the increased potency in competition assays. Therefore, this suggests a role of the blocking loop in the thioester switch releasing BIRC6–Ub (Fig. 5j).

**Table 2 | Summary of data collection and model refinement parameters for structures generated from the UBA6–UbDha–BIRC6<sup>UBC</sup> and dUBA1–UbDha–dBIRC6<sup>UBC</sup> datasets**

	UBA6–UbDha–BIRC6 <sup>UBC</sup> (doubly loaded) Consensus	UBA6–UbDha–BIRC6 <sup>UBC</sup> (doubly loaded) Cluster 0	UBA6–UbDha–BIRC6 <sup>UBC</sup> (doubly loaded) Cluster 2	UBA6–UbDha–BIRC6 <sup>UBC</sup> (singly loaded) Consensus	dUBA1–UbDha–dBIRC6 <sup>UBC</sup> (doubly loaded) Consensus	dUBA1–UbDha–dBIRC6 <sup>UBC</sup> (doubly loaded) Cluster 2	dUBA1–UbDha–dBIRC6 <sup>UBC</sup> (doubly loaded) Cluster 4
	EMD-53155	EMD-53170	EMD-53183	EMD-53149	EMD-53130	EMD-53131	EMD-53147
	PDB 9QH5	PDB 9QHI	PDB 9QIA	PDB 9QGW	PDB 9QGG	PDB 9QGI	PDB 9QGR
<b>Data collection and processing</b>							
Microscope	Krios (COSMIC)	Krios (COSMIC)	Krios (COSMIC)	Krios (COSMIC)	Krios (COSMIC)	Krios (COSMIC)	Krios (COSMIC)
Magnification	×105,000	×105,000	×105,000	×105,000	×105,000	×105,000	×105,000
Voltage (kV)	300	300	300	300	300	300	300
Detector	K3 BioQuantum	K3 BioQuantum	K3 BioQuantum	K3 BioQuantum	K3 BioQuantum	K3 BioQuantum	K3 BioQuantum
Slit width (eV)	20	20	20	20	20	20	20
Electron exposure (e <sup>-</sup> per Å <sup>2</sup> )	37.84	37.84	37.84	37.84	36.1	36.1	36.1
Defocus range (μm)	-0.5, -2.5	-0.5, -2.5	-0.5, -2.5	-0.5, -2.5	-0.5, -2.5	-0.5, -2.5	-0.5, -2.5
Pixel size (Å) <sup>1</sup>	0.85	0.85	0.85	0.85	0.83	0.83	0.83
Symmetry imposed	C <sub>1</sub>	C <sub>1</sub>	C <sub>1</sub>	C <sub>1</sub>	C <sub>1</sub>	C <sub>1</sub>	C <sub>1</sub>
Micrographs (no.)	13,888	13,888	13,888	13,888	15,362	15,362	15,362
Picking software	SIMPLE	SIMPLE	SIMPLE	SIMPLE	SIMPLE	SIMPLE	SIMPLE
Initial particle images (no.)	4,653,678	4,653,678	4,653,678	4,653,678	7,193,985	7,193,985	7,193,985
Final particle images (no.)	188,172	9,014	6,504	170,986	333,479	23,467	20,475
Map resolution (Å)	3.09	4.27	4.38	3.62	2.58	3.16	3.10
FSC threshold	0.143	0.143	0.143	0.143	0.143	0.143	0.143
Map resolution range: 25th, 75th percentile (Å)	3.22, 6.73	6.06, 10.04	7.05, 11.04	3.67, 7.59	2.62, 5.79	3.57, 8.26	3.47, 8.28
<b>Refinement</b>							
Initial model used (PDB code)	9B5C, AlphaFold prediction	9B5C, AlphaFold prediction	9B5C, AlphaFold prediction	9B5C, AlphaFold prediction	9B5C, AlphaFold prediction	9B5C, AlphaFold prediction	9B5C, AlphaFold prediction
Model resolution (Å)	3.4	4.8	7.1	3.7	2.8	3.3	3.3
FSC threshold	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Model resolution range: 25th, 75th percentile (Å)	3.22, 6.73	6.06, 10.04	7.05, 11.04	3.67, 7.59	2.62, 5.79	3.57, 8.26	3.47, 8.28
Map sharpening B factor (Å <sup>2</sup> )	124.9	86.6	79.8	151.1	100.5	76.8	73.8
<b>Model composition</b>							
Nonhydrogen atoms	10,848	11,421	11,430	10,254	10,730	11,312	11,312
Protein residues	1,358	1,430	1,431	1,282	1,349	1,422	1,422
Ligands	2	2	2	2	1	1	1
<b>B factors (Å<sup>2</sup>)</b>							
Protein	189.08	247.73	249.07	166.92	119.51	125.99	146.47
Ligand	203.46	271.87	245.23	187.82	108.51	98.47	129.74
<b>R.m.s.d.</b>							
Bond lengths (Å)	0.005	0.004	0.004	0.004	0.006	0.005	0.006
Bond angles (°)	0.943	0.946	0.962	0.490	0.993	0.964	1.033
<b>Validation</b>							
MolProbity score	1.02	1.87	1.56	1.09	1.04	1.20	1.24
Clashscore	2.36	11.53	9.03	3.04	2.57	4.21	4.70
Poor rotamers (%)	1.00	2.45	0.71	0.80	0.85	0.80	0.64
<b>Ramachandran plot</b>							
Favored (%)	98.22	98.03	97.61	98.12	98.95	98.37	98.58
Allowed (%)	1.78	1.97	2.39	1.88	1.05	1.63	1.42
Disallowed (%)	0.00	0.00	0.00	0.00	0.00	0.00	0.00

<sup>1</sup>Pixel size was recalibrated between sessions.

## The UBA6 Cys-Cap loop modulates E2 binding

Having determined changes in BIRC6 that are involved in release of BIRC6-Ub, we analyzed our BIRC6<sup>OUT</sup> and BIRC6-Ub loaded structures for complementary features in UBA6.

In our UBA6-BIRC6<sup>UBC-OUT</sup> structure, we observed the BIRC6<sup>UBC</sup> catalytic site in proximity to the UBA6 Cys-Cap loop (Fig. 6a). This Cys-Cap loop is disordered in both UBA6-BIRC6<sup>UBC-IN</sup> and UBA6-UbDha-BIRC6<sup>UBC</sup> structures. To investigate any contribution of the Cys-Cap loop in the UBA6-BIRC6 interaction, we generated a UBA6  $\Delta$ Cys-Cap loop construct where the Cys-Cap loop (residues 797–819) were replaced by an 8-amino acid glycine/serine-rich linker. Shortening the Cys-Cap loop did not affect loading of weaker-binding E2s (UBE2D2, UBE2Z and the BIRC6<sup>UBC</sup>-A4575D mutant) in transthiolation reactions (Fig. 6b,c and Supplementary Fig. 4b). However, the observed rate of BIRC6<sup>UBC</sup> loading was significantly impaired (50% completion after 30 min) compared to WT UBA6 (75% completion under 10 min) (Fig. 6b,c). We tested whether this impairment was because of decreased recruitment to UBA6  $\Delta$ Cys-Cap loop or poor release of the BIRC6-Ub thioester product. Binding measurements revealed that BIRC6<sup>UBC</sup> binds to UBA6  $\Delta$ Cys-Cap loop with tenfold greater affinity than to UBA6 (Fig. 6d), suggesting that BIRC6 recruitment is not impaired in the absence of the Cys-Cap loop; rather, it is significantly enhanced. Furthermore, the stable BIRC6<sup>UBC</sup>-Ub conjugate binds to UBA6  $\Delta$ Cys-Cap loop severalfold tighter than to WT UBA6 (Fig. 6d). Loss of the Cys-Cap loop, therefore, effectively overpowers the thioester switch, thus inhibiting release of the BIRC6-Ub product. Consistent with this combined affinity effect, BIRC6<sup>UBC</sup> now outcompetes UBE2D2 for receiving ubiquitin from UBA6  $\Delta$ Cys-Cap loop to a similar extent to catalytically inactive BIRC6<sup>UBC</sup>-C4666A (Fig. 6e,f and Supplementary Fig. 4c).

For E2s with no detectable affinity to UBA6 WT, such as UBE2Z and BIRC6-A4575D (Fig. 2g), we began to detect binding upon loss of the Cys-Cap loop and, in some cases, determined a low-micromolar affinity (BIRC6-A4575D) (Supplementary Fig. 5b); thus, removal of the Cys-Cap loop results in a pan-E2 increased affinity. However, this increase in binding is still not sufficient to enable priority of UBE2Z or BIRC6-A4575D over UBE2D2 (Fig. 6e,f) compared to BIRC6 WT.

We next aimed to assess this tight BIRC6-UBA6 interaction in cellulo through transfecting StrepII-GFP-tagged variants of catalytically active and inactive UBA6 into HEK293T cells. Isolation of full-length, active UBA6 detected a low level of endogenous BIRC6; this level increased with UBA6-C625A, consistent with the requirement of the thioester switch for BIRC6 release. We observed a notable enrichment of endogenous BIRC6 with UBA6  $\Delta$ Cys-Cap loop, either catalytically active or inactive (Fig. 6g), consistent with our findings that BIRC6 affinity dramatically increases and it cannot be released even once ubiquitin is transferred (Fig. 6d). Lastly, a UBA6 chimera with the UBA1 UFD (UBA6-1UFD) (Extended Data Fig. 1c) did not enrich endogenous BIRC6, consistent with BIRC6 recruitment to UBA6 being driven through the UFD (Extended Data Fig. 1d).

## Discussion

### Molecular framework for E1-E2 specificity in the ubiquitin cascade

Amongst protein post-translational attachments, ubiquitylation is unique in the number and diversity of enzymes involved with two E1s and 29 E2s compared to other UBL cascades. Since the discovery of UBA6-activated ubiquitylation pathways nearly 20 years ago, the specificity underpinning UBA6-specific pathways has remained unclear. Our UBA1/UBA6-E2 reactivity profile of all 29 ubiquitin-conjugating E2s revealed that determinants driving E2 specificity for UBA1 and UBA6 can be grouped into distinct categories, forming a molecular framework defining ubiquitin E1-E2 specificity and addressing a longstanding question. Building from this, we provide the molecular basis for generating specificity-changing mutants of E2 enzymes that could be used to separate their functions within UBA1 and UBA6 independent pathways.

We show that ubiquitin E2s take advantage of a variety of mechanisms to achieve specificity, involving recognition of the UFD, SCCH domain or both E2-interacting domains of their cognate E1s. For some dual-specific E2s, such as UBE2L3, the UFD and SCCH requirements for activity differ depending on UBA1 versus UBA6, suggesting that the E2 uses different recognition strategies for the E1 it encounters (Extended Data Fig. 1d). At the UFD, we show that UBA6 uses a hydrophobic surface to exclude charged side chains found in UBA1-specific E2s. Conversely, the topological arrangement of the SCCH domain differs between UBA1 and UBA6 (Extended Data Fig. 10c), providing differences for E2s to exploit for selectivity. We showed that direct interactions between helix 1 and the UFD determine specificity for UBE2E1, UBE2H and UBE2W, consistent with known E1-E2 specificity determinants in other cascades<sup>24–27</sup>. In addition, we found that even E2s harboring bispecific E1 interaction motifs within their UBC core can achieve specificity through N-terminal or C-terminal extensions. This provides a new role for UBC extensions within the ubiquitin cascade, alongside previously studied functions in ubiquitin chain formation<sup>40–42</sup>, substrate promiscuity<sup>43</sup> and recruitment to E3 complexes<sup>44</sup>. Given that extensions are found in the majority (62%) of E2 enzymes<sup>51</sup> (Supplementary Fig. 3a), this may be a specificity determinant for other E2s.


Interestingly, the two UBA6-specific E2s use completely different mechanisms to achieve specificity. UBE2Z is the only E2 whose specificity is solely driven by the SCCH domain. On the other hand, multiple interactions across BIRC6 prevent it from charging with UBA1. Given that *Drosophila* lack UBA6, the altered specificity of dBIRC6 is necessary to carry out ubiquitin-dependent BIRC6 functions<sup>46,47</sup>. Through our evolution-guided approach, we observed that both BIRC6 orthologs contact their cognate E1 enzymes through multiple interfaces in our cryo-EM structures. Experiments using both chimeric E1 and BIRC6 constructs (Extended Data Fig. 1d and Fig. 4h) demonstrated that, while all E1-E2 contacts contribute to maximum transthiolation activity for BIRC6, the UFD interface is still most important for driving E1 specificity. Unlike the UBA1-specific E2s tested in Fig. 3c, whose specificity could be changed by mutations within helix 1, we localized specificity determinants in BIRC6 to a key pair of residues (E4603 and E4604) in loop 2. Together, these results demonstrate how nature achieves differential E1 specificity between near-identical protein orthologs.

### BIRC6 priority and thioester switch

Our work uncovered a hierarchy amongst UBA6-active ubiquitin E2s with BIRC6 having overall precedent. Our structural and functional analyses outlined the full progression of ubiquitin transfer from UBA6 to BIRC6, explaining how BIRC6 priority is achieved without inhibition of UBA6. High-affinity interactions with UBA6<sup>UFD</sup> enable BIRC6 to be preferentially recruited. Conformational changes in UBA6 (Cys-Cap loop displacement) and BIRC6 (blocking loop opening) allow recruitment of BIRC6 and ubiquitin transfer to occur, respectively. BIRC6-Ub is then released through a thioester switch mechanism involving the BIRC6 blocking loop, preventing UBA6 inhibition by BIRC6 (Figs. 5j and 6h).

Why might a UBA6-BIRC6 priority mechanism have arisen? BIRC6 is an essential regulator of cell death, autophagy and development that requires its ubiquitylation activity<sup>18,19,52–56</sup>. In line with this, BIRC6 ubiquitylation activity is exploited by certain cancer cells for their survival, evidenced by its strong codependency with UBA6 (ref. 16) (Fig. 1e). However, UBA6 may be limiting in cells as UBA6 expression is approximately tenfold less than UBA1 (refs. 8,57) and it has been shown that only half of the UBA6 cellular pool is loaded with ubiquitin<sup>8</sup>. Furthermore, BIRC6 expression levels are lower than many other UBA6-active E2 enzymes<sup>57</sup>. Therefore, to maintain the required BIRC6 ubiquitylation competency, a mechanism enabling preferential access of BIRC6 to UBA6 would be necessary. We did not observe an equivalent priority mechanism for the only other UBA6-specific E2 UBE2Z. UBE2Z is known to function with the UBA6-specific UBL FAT10, whereas other





**Fig. 6 | The UBA6 Cys-Cap loop modulates E2 affinity. a**, Close-up view of the UBA6 Cys-Cap loop in the UBA6-BIRC6<sup>UBC-OUT</sup> state. **b**, SDS-PAGE analysis of E2-Ub thioester formation over a 30-min time course for E2s (BIRC6<sup>UBC</sup>, BIRC6<sup>UBC</sup>-A4575D, UBE2Z and UBE2D2) with UBA6 WT (left) and UBA6 ΔCys-cap loop (right). Gels are representative of three independent technical replicates. **c**, Quantification of E2-Ub thioester formation by UBA6 WT (top) and UBA6 ΔCys-Cap loop (bottom) from **b** (mean ± s.d.). Statistical analysis of E2 loading by UBA6 WT and UBA6 ΔCys-Cap loop at each time point is presented in Supplementary Fig. 4b. **d**, Fluorescence polarization measurements of full-length UBA6 WT and UBA6 ΔCys-Cap loop binding to unloaded and stable ubiquitin-loaded Cy5-labeled BIRC6<sup>UBC</sup>. Increased binding to UBA6 ΔCys-Cap loop was detected for both loading states of BIRC6<sup>UBC</sup> (unloaded, K<sub>d</sub>: 10 ± 2 nM; loaded, K<sub>d</sub>: 22 ± 10 nM). Data shown are the mean ± s.d. from two independent experiments, each performed in technical triplicate. **e**, SDS-PAGE analysis of multiple-turnover UBE2D2-Ub thioester formation by UBA6 ΔCys-Cap loop at a 5-min end point in the presence of increasing concentrations of

either active or inactive competitor E2s (BIRC6<sup>UBC</sup>-C4666A, UBE2Z-C188A and BIRC6<sup>UBC</sup>-A4575D;C4666A). Gels are representative of three independent technical replicates. **f**, Quantification of UBE2D2-Ub thioester formation from **e** (mean ± s.d.). Statistical analysis of each end point relative to UBE2D2 without competition is presented in Supplementary Fig. 4c. **g**, Western blot analysis of isolated StrepII-GFP UBA6 variants exogenously expressed in HEK293T cells showing that endogenous BIRC6 forms a stable complex with UBA6 that is markedly enhanced upon loss of the UBA6 Cys-Cap loop. Results are representative of three independent experiments. **h**, Schematic summarizing the effect of the UBA6 Cys-Cap loop on E2 recruitment. Positioning of the Cys-Cap loop over the catalytic Cys lowers affinity toward incoming BIRC6 and E2s in general. Ubiquitin loading at the E1 catalytic cysteine may induce partial dissociation of the Cys-Cap loop, promoting E2 recruitment to the ubiquitin-loaded E1 complex, which is mirrored by deletion of the Cys-Cap loop strengthening the E1-E2 interaction.

UBA6-active E2s, including BIRC6, are much less capable of receiving FAT10 (ref. 20). We, therefore, suggest that a UBL-dictated priority route for UBE2Z may negate the need for the high-affinity-mediated priority mechanism identified for BIRC6.

We propose that the unique high affinity of the UBA6-BIRC6 interaction requires specific structural elements in both enzymes to avoid UBA6 inhibition. First, the blocking loop of BIRC6 contributes to its release after ubiquitin transfer, reducing E2 competition

(Fig. 5g). Release of loaded E2s from UBA1 is facilitated by transition of the transferred ubiquitin from the UBA1 FCCH domain to the E2, reducing the number of contacts to the E1 (ref. 35). Alternate thioester switching mechanisms have been described for the NEDD8 and SUMO systems, in which a large rotation of the E1 UFD destabilizes binding to the thioester product<sup>33</sup>. Ubiquitin E2s generally have weaker affinities to their cognate E1s than those of the NEDD8 and SUMO systems, which would explain why they require a less sophisticated release mechanism. Beyond BIRC6, extended blocking loops are also found in the UBE2R, UBE2G, UBE2J subfamilies and UBE2O, UBE2T and UBE2Z. In UBE2R1 (Cdc34) and UBE2G2, this loop is required for ubiquitin chain elongation but not monoubiquitylation<sup>58–60</sup>; however, the function of the blocking loop in other E2s is not known. We cannot rule out that these structural elements may also contribute to release of these E2s and we envisage that further structural studies of trapped transthiolation states using the UbDha technique would aid the exploration of these mechanisms. Recent structural data correlated E1–E2 ubiquitin transfer to progression through the E1 adenylation reaction<sup>36</sup>, supporting earlier biochemical experiments suggesting that the reactions are coupled<sup>61,62</sup>. As these results were shown for Ubc4 (the yeast ortholog of UBE2D2), which does not contain an extended blocking loop, we believe that this coupling is independent of the blocking loop mechanism described here for BIRC6.

Secondly, we showed that the Cys-Cap loop reduces the affinities of E2 enzymes to UBA6 (Fig. 2g and Supplementary Fig. 5b) and this is critical for preventing stalling of BIRC6 on UBA6 (Fig. 6b,e,g). Among canonical E1 enzymes, Cys-Cap loops of varying lengths are present in UBA1, UBA2 and UBA7; UBA3 lacks an analogous loop. Although Cys-Cap loop remodeling takes place during both thioester bond formation and transthiolation reactions of UBA1 (refs. 63,64) (Fig. 1a, ii, iv), its only attributed function to date is protection of the catalytic cysteine from oxidation<sup>63</sup>. Recently, extending the Cys-Cap loop of UBA7 (which is shorter than those found in UBA1 and UBA6) was shown to reduce the affinity of UBA7 to its cognate E2 UBE2L6, thereby preventing the formation of disulfide-linked E1–E2 adducts<sup>32</sup>. Consistent with this, our data suggest a general function of the UBA6 Cys-Cap loop in dampening E1–E2 interactions. Therefore, we propose that the Cys-Cap loop may provide temporal modulation of the E2 interaction; the Cys-Cap loop becomes displaced upon loading of ubiquitin onto the E1 catalytic site, which results in an increased E1–E2 affinity that may then promote and assist E2 recruitment (Fig. 6h). This could explain previous observations that E2s bind more effectively to doubly loaded E1 enzymes<sup>5</sup> (Fig. 1a).

Together, our results show how UBA6 and BIRC6 both coopt structural elements present in other enzymes to accommodate their high-affinity interaction, underscoring the importance of UBA6–BIRC6-dependent pathways for cell function. Lastly, our findings propose a concept of E2 hierarchy for activity, which explains how less abundant ubiquitin E2s, such as BIRC6, gain access to E1s to orchestrate E2-specific cellular functions.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41594-025-01717-z>.

## References

- Komander, D. & Rape, M. The ubiquitin code. *Annu. Rev. Biochem.* **81**, 203–229 (2012).
- Rape, M. Ubiquitylation at the crossroads of development and disease. *Nat. Rev. Mol. Cell Biol.* **19**, 59–70 (2018).
- Swatek, K. N. & Komander, D. Ubiquitin modifications. *Cell Res.* **26**, 399–422 (2016).
- Pickart, C. M. Mechanisms underlying ubiquitination. *Biochemistry* **70**, 503–533 (2001).
- Hershko, A., Heller, H., Elias, S. & Ciechanover, A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. *J. Biol. Chem.* **258**, 8206–8214 (1983).
- Ciechanover, A., Finley, D. & Varshavsky, A. Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. *Cell* **37**, 57–66 (1984).
- Finley, D., Ciechanover, A. & Varshavsky, A. Thermolability of ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85. *Cell* **37**, 43–55 (1984).
- Jin, J., Li, X., Gygi, S. P. & Harper, J. W. Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. *Nature* **447**, 1135–1138 (2007).
- Chiu, Y.-H., Sun, Q. & Chen, Z. J. E1-L2 activates both ubiquitin and FAT10. *Mol. Cell* **27**, 1014–1023 (2007).
- Pelzer, C. et al. UBE1L2, a novel E1 enzyme specific for ubiquitin. *J. Biol. Chem.* **282**, 23010–23014 (2007).
- Poulter, J. A. et al. Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. *Blood* **137**, 3676–3681 (2021).
- Collins, J. C. et al. Shared and distinct mechanisms of UBA1 inactivation across different diseases. *EMBO J.* **43**, 1919–1946 (2024).
- Lee, P. C. W. et al. Altered social behavior and neuronal development in mice lacking the Uba6–Use1 ubiquitin transfer system. *Mol. Cell* **50**, 172–184 (2013).
- Amer-Sarsour, F. et al. Disease-associated polyalanine expansion mutations impair UBA6-dependent ubiquitination. *EMBO J.* **43**, 250–276 (2024).
- Andreev, V. P. et al. Label-free quantitative LC–MS proteomics of Alzheimer’s disease and normally aged human brains. *J. Proteome Res.* **11**, 3053–3067 (2012).
- Cervia, L. D. et al. A ubiquitination cascade regulating the integrated stress response and survival in carcinomas. *Cancer Discov.* **13**, 766–795 (2022).
- Liu, X. et al. Orthogonal ubiquitin transfer identifies ubiquitination substrates under differential control by the two ubiquitin activating enzymes. *Nat. Commun.* **8**, 14286 (2017).
- Jia, R. & Bonifacino, J. S. Negative regulation of autophagy by UBA6–BIRC6-mediated ubiquitination of LC3. *Elife* **8**, e50034 (2019).
- Ebner, P. et al. The IAP family member BRUCE regulates autophagosome–lysosome fusion. *Nat. Commun.* **9**, 599 (2018).
- Dietz, L. et al. Structural basis for SMAC-mediated antagonism of caspase inhibition by the giant ubiquitin ligase BIRC6. *Science* **379**, 1112–1117 (2023).
- Hunkeler, M., Jin, C. Y. & Fischer, E. S. Structures of BIRC6–client complexes provide a mechanism of SMAC-mediated release of caspases. *Science* **379**, 1105–1111 (2023).
- Ehrmann, J. F. et al. Structural basis for regulation of apoptosis and autophagy by the BIRC6/SMAC complex. *Science* **379**, 1117–1123 (2023).
- Cappadocia, L. & Lima, C. D. Ubiquitin-like protein conjugation: structures, chemistry, and mechanism. *Chem. Rev.* **118**, 889–918 (2018).
- Tokgöz, Z. et al. E1–E2 interactions in ubiquitin and Nedd8 ligation pathways. *J. Biol. Chem.* **287**, 311–321 (2012).
- Afsar, M. et al. Cryo-EM structures of Uba7 reveal the molecular basis for ISG15 activation and E1–E2 thioester transfer. *Nat. Commun.* **14**, 4786 (2023).
- Wallace, I. et al. Insights into the ISG15 transfer cascade by the UBE1L activating enzyme. *Nat. Commun.* **14**, 7970 (2023).
- Olsen, S. K. & Lima, C. D. Structure of a ubiquitin E1–E2 complex: insights to E1–E2 thioester transfer. *Mol. Cell* **49**, 884–896 (2013).

28. Walden, H., Podgorski, M. S. & Schulman, B. A. Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8. *Nature* **422**, 330–334 (2003).
29. Huang, D. T., Zhuang, M., Ayrault, O. & Schulman, B. A. Identification of conjugation specificity determinants unmasks vestigial preference for ubiquitin within the NEDD8 E2. *Nat. Struct. Mol. Biol.* **15**, 280–287 (2008).
30. Durfee, L. A., Kelley, M. L. & Huibregtse, J. M. The basis for selective E1–E2 interactions in the ISG15 conjugation system. *J. Biol. Chem.* **283**, 23895–23902 (2008).
31. Tsherniak, A. et al. Defining a cancer dependency map. *Cell* **170**, 564–576 (2017).
32. Chen, P.-T., Yeh, J.-Y., Weng, J.-H. & Wu, K.-P. Elucidating the mechanism underlying UBA7•UBE2L6 disulfide complex formation. *Elife* **14**, RP105638 (2025).
33. Huang, D. T. et al. Basis for a ubiquitin-like protein thioester switch toggling E1–E2 affinity. *Nature* **445**, 394–398 (2007).
34. Williams, K. M. et al. Structural insights into E1 recognition and the ubiquitin-conjugating activity of the E2 enzyme Cdc34. *Nat. Commun.* **10**, 3296 (2019).
35. Yuan, L., Lv, Z., Adams, M. J. & Olsen, S. K. Crystal structures of an E1–E2–ubiquitin thioester mimetic reveal molecular mechanisms of transthioesterification. *Nat. Commun.* **12**, 2370 (2021).
36. Kochańczyk, T. et al. Structural basis for transthioesterification intermediates in the ubiquitin pathway. *Nature* **633**, 216–223 (2024).
37. Winn, P. J., Religa, T. L., Batten, J. N. D., Banerjee, A. & Wade, R. C. Determinants of functionality in the ubiquitin conjugating enzyme family. *Structure* **12**, 1563–1574 (2004).
38. Huang, D. T. et al. Structural basis for recruitment of Ubc12 by an E2 binding domain in NEDD8's E1. *Mol. Cell* **17**, 341–350 (2005).
39. Wang, J., et al. Crystal structure of UBA2<sup>ubd</sup>–Ubc9: insights into E1–E2 interactions in Sumo pathways. *PLoS ONE* **5**, e15805 (2010).
40. Schumacher, F.-R., Wilson, G. & Day, C. L. The N-terminal extension of UBE2E ubiquitin-conjugating enzymes limits chain assembly. *J. Mol. Biol.* **425**, 4099–4111 (2013).
41. Kolman, C. J., Toth, J. & Gonda, D. K. Identification of a portable determinant of cell cycle function within the carboxyl-terminal domain of the yeast CDC34 (UBC3) ubiquitin conjugating (E2) enzyme. *EMBO J.* **11**, 3081–3090 (1992).
42. Spratt, D. E. & Shaw, G. S. Association of the disordered C-terminus of CDC34 with a catalytically bound ubiquitin. *J. Mol. Biol.* **407**, 425–438 (2011).
43. Summers, M. K., Pan, B., Mukhyala, K. & Jackson, P. K. The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC. *Mol. Cell* **31**, 544–556 (2008).
44. Brown, N. G. et al. Mechanism of polyubiquitination by human anaphase-promoting complex: RING repurposing for ubiquitin chain assembly. *Mol. Cell* **56**, 246–260 (2014).
45. Huang, D. T. et al. A unique E1–E2 interaction required for optimal conjugation of the ubiquitin-like protein NEDD8. *Nat. Struct. Mol. Biol.* **11**, 927–935 (2004).
46. Domingues, C. & Ryo, H. D. *Drosophila* BRUCE inhibits apoptosis through non-lysine ubiquitination of the IAP-antagonist REAPER. *Cell Death Differ.* **19**, 470–477 (2011).
47. Vernooy, S. Y. et al. *Drosophila* BRUCE can potently suppress Rpr and Grim-dependent but not Hid-dependent cell death. *Curr. Biol.* **12**, 1164–1168 (2002).
48. Liu, S.-S. et al. Molecular mechanisms underlying the BIRC6-mediated regulation of apoptosis and autophagy. *Nat. Commun.* **15**, 891 (2024).
49. Mulder, M. P. C. et al. A cascading activity-based probe sequentially targets E1–E2–E3 ubiquitin enzymes. *Nat. Chem. Biol.* **12**, 523–530 (2016).
50. Schulman, B. A. & Harper, J. W. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. *Nat. Rev. Mol. Cell Biol.* **10**, 319–331 (2009).
51. Wijk, S. J. L. van & Timmers, H. T. M. The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. *FASEB J.* **24**, 981–993 (2010).
52. Bartke, T., Pohl, C., Pyrowolakis, G. & Jentsch, S. Dual Role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. *Mol. Cell* **14**, 801–811 (2004).
53. Ren, J. et al. The *Birc6* (BRUCE) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. *Proc. Natl Acad. Sci. USA* **102**, 565–570 (2005).
54. Lotz, K., Pyrowolakis, G. & Jentsch, S. BRUCE, a giant E2/E3 ubiquitin ligase and inhibitor of apoptosis protein of the *trans*-Golgi network, is required for normal placenta development and mouse survival. *Mol. Cell. Biol.* **24**, 9339–9350 (2004).
55. Pohl, C. & Jentsch, S. Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. *Cell* **132**, 832–845 (2008).
56. Hao, Y. et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. *Nat. Cell Biol.* **6**, 849–860 (2004).
57. Itzhak, D. N., Tyanova, S., Cox, J. & Borner, G. H. Global, quantitative and dynamic mapping of protein subcellular localization. *Elife* **5**, e16950 (2016).
58. Petroski, M. D. & Deshaies, R. J. Mechanism of lysine 48-linked ubiquitin-chain synthesis by the Cullin-RING ubiquitin-ligase complex SCF–Cdc34. *Cell* **123**, 1107–1120 (2005).
59. Liwocha, J. et al. Mechanism of millisecond Lys48-linked poly-ubiquitin chain formation by Cullin-RING ligases. *Nat. Struct. Mol. Biol.* **31**, 378–389 (2024).
60. Li, W., Tu, D., Brunger, A. T. & Ye, Y. A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate. *Nature* **446**, 333–337 (2007).
61. Pickart, C. M., Kasperek, E. M., Beal, R. & Kim, A. Substrate properties of site-specific mutant ubiquitin protein (G76A) reveal unexpected mechanistic features of ubiquitin-activating enzyme (E1). *J. Biol. Chem.* **269**, 7115–7123 (1994).
62. Tokgöz, Z., Bohnsack, R. N. & Haas, A. L. Pleiotropic effects of ATP-Mg<sup>2+</sup> binding in the catalytic cycle of ubiquitin-activating enzyme. *J. Biol. Chem.* **281**, 14729–14737 (2006).
63. Olsen, S. K., Capili, A. D., Lu, X., Tan, D. S. & Lima, C. D. Active site remodelling accompanies thioester bond formation in the SUMO E1. *Nature* **463**, 906–912 (2010).
64. Hann, Z. S. et al. Structural basis for adenylation and thioester bond formation in the ubiquitin E1. *Proc. Natl Acad. Sci. USA* **116**, 15475–15484 (2019).
65. Chrustowicz, J. et al. Multisite phosphorylation dictates selective E2–E3 pairing as revealed by Ubc8/UBE2H–GID/CTLH assemblies. *Mol. Cell* **84**, 293–308 (2024).
66. Kiss, L. et al. Trim-Away ubiquitinates and degrades lysine-less and N-terminally acetylated substrates. *Nat. Commun.* **14**, 2160 (2023).
67. Özkan, E., Yu, H. & Deisenhofer, J. Mechanistic insight into the allosteric activation of a ubiquitin-conjugating enzyme by RING-type ubiquitin ligases. *Proc. Natl Acad. Sci. USA* **102**, 18890–18895 (2005).
68. Yariv, B., et al. Using evolutionary data to make sense of macromolecules with a ‘face-lifted’ ConSurf. *Protein Sci.* **32**, e4582 (2023).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in

a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025

## Methods

### Protein expression and purification from Sf9 (E1 enzymes, UBE20, full-length BIRC6)

Sequences were cloned into the vectors indicated in Supplementary Table 1. Vectors were transformed into DH10Bac cells (Invitrogen). Bac-mids were isolated and transfected into *Spodoptera frugiperda* Sf9 cells to produce initial baculovirus and subsequently amplified in a larger volume of Sf9 cells. Amplified virus was used to infect 1-L cultures of Sf9 cells, which were harvested 72 h after infection. Cell pellets were resuspended in a buffer containing 20 mM Tris pH 8.5, 200 mM NaCl, 4 mM DTT and 10% (v/v) glycerol, supplemented with cOmplete protease inhibitor tablets (Roche), 1  $\mu$ M pepstatin, 2  $\mu$ M leupeptin, 1 mM PMSF and 0.5% (v/v) Tween-20, and lysed through manual homogenization followed by sonication. The lysate was clarified by centrifugation at 4,000g for 20 min and applied to Strep-Tactin XT 4-Flow resin (IBA). Proteins were eluted by incubation with 3C protease, diluted into anion-exchange buffer (20 mM Tris pH 8.5 and 4 mM DTT) for purification by anion-exchange chromatography (Resource Q, Cytiva) and eluted with a linear gradient of 1 M NaCl. Finally, proteins were purified by SEC (Superdex 200, Cytiva for E1 enzymes and UBE20; Superose 6, Cytiva for full-length BIRC6) in 20 mM HEPES pH 7.5, 200 mM NaCl and 4 mM DTT. Proteins were concentrated, flash-frozen in single-use aliquots and stored at  $-75^{\circ}\text{C}$  before use.

### Protein expression and purification from *Escherichia coli* (ubiquitin, E2 enzymes, UBA6 UFD)

Sequences were cloned into the vectors indicated in Supplementary Table 1 and transformed into Rosetta (DE3) *E. coli* for expression. *E. coli* cultures were grown in 2 $\times$ TY medium supplemented with 34  $\mu\text{g ml}^{-1}$  chloramphenicol and 30  $\mu\text{g ml}^{-1}$  kanamycin and induced with 400  $\mu\text{M}$  IPTG at 18  $^{\circ}\text{C}$  overnight. Cells were harvested by centrifugation at 4,000 rpm. Ubiquitin (WT, MC-, G76C) was purified as previously described<sup>69</sup>. For WT, mutant and chimeric E2 enzymes, cell pellets were resuspended in a buffer containing 20 mM Tris pH 8.5, 300 mM NaCl, 2 mM  $\beta$ -mercaptoethanol ( $\beta$ -ME), 20 mM imidazole and protease inhibitors (1  $\mu$ M pepstatin, 2  $\mu$ M leupeptin and 1 mM PMSF). Cells were lysed by sonication and the lysate was clarified by centrifugation at 18,000 rpm for 45 min. Recombinant proteins were purified using immobilized metal affinity chromatography and eluted in buffer containing 20 mM Tris pH 8.5, 300 mM NaCl, 2 mM  $\beta$ -ME and 500 mM imidazole. Eluted proteins were dialyzed overnight with SENP1 or 3C protease to cleave affinity tags and remove excess imidazole. Subsequently, proteins were either directly purified by SEC (Superdex 75, Cytiva) in 20 mM HEPES pH 7.5, 200 mM NaCl and 4 mM DTT or first subjected to ion-exchange chromatography (Resource Q or S, Cytiva) by dialyzing overnight into either low-salt anion-exchange buffer (20 mM Tris pH 8.5 and 4 mM DTT) or low-salt cation-exchange buffer (20 mM MES pH 6.5 and 4 mM DTT) and eluted from the ion-exchange column by a salt gradient up to 1 M NaCl. Proteins were concentrated, flash-frozen in single-use aliquots and stored at  $-75^{\circ}\text{C}$  before use.

### Fluorescent labeling of proteins

Ubiquitin containing a cysteine introduced at the N terminus was reacted in 20 mM HEPES pH 7.4 and 200 mM NaCl with 20-fold molar excess of BDP FL maleimide (Lumiprobe) dissolved in DMSO. The labeling reaction was incubated overnight at 4  $^{\circ}\text{C}$  protected from light, followed by purification of fluorescently labeled ubiquitin from unreacted dye by SEC (Superdex 75, Cytiva) in 20 mM HEPES pH 7.4 and 200 mM NaCl.

### UbDha probe generation

Purified ubiquitin-G76C in 50 mM sodium phosphate (pH 8.0) was mixed with 2,5-dibromohexanediamide (DBHDA) (Bio-Techne) solubilized in DMSO with final concentrations of 2  $\text{mg ml}^{-1}$  ubiquitin and 5.5  $\text{mg ml}^{-1}$  DBHDA (a tenfold molar excess of DBHDA to ubiquitin).

The reaction was incubated overnight at 37  $^{\circ}\text{C}$ , followed by separation of UbDha from unreacted starting materials by SEC (Superdex 75, Cytiva) in 50 mM NaPO<sub>4</sub> (pH 8.0).

### E1–UbDha–E2 trapped ternary complex formation

Purified UBA6 C625S (4  $\mu\text{M}$ ) was loaded with UbDha (40  $\mu\text{M}$ ) overnight in a reaction buffer containing 20 mM HEPES pH 7.5, 200 mM NaCl, 0.5 mM DTT, 5 mM MgCl<sub>2</sub> and 10 mM ATP at room temperature. After loading, E2 was added to a final concentration of 10  $\mu\text{M}$  and reacted for 2 h at room temperature. The dUBA1–UbDha–dBIRC6 reaction was performed with WT dUBA1 and reagent concentrations identical to those described above; however, both UbDha and E2 were added together during the overnight reaction.

### Tissue gene expression analysis

Data were downloaded from the GTEX Portal and normalized using the median of ratios method as described previously<sup>70</sup>. The Spearman rank correlation coefficient was computed across all samples from all tissues and corrected for multiple testing using Bonferroni. This information was used to plot a heat map where the color was proportional to the value of the correlation coefficient. Only correlations with significant *P* values < 0.01 after multiple-test correction were shown in color. Code to reproduce the analysis and figures is available on GitHub (<https://github.com/SarkiesLab/UBESpec>).

### BIRC6 and UBA6 metazoan taxa analysis

All UniProt sequences corresponding to full-length E1 isoforms (UBA1, UBA6 and UBA7) were identified by generalized profile searches covering the SCCH domain and other catalytically important regions<sup>71</sup>. The full-length sequences were clustered using clans<sup>72</sup>, resulting in a clear separation of UBA1-like, UBA6-like and UBA7-like clusters. Sequences within the UBA6 cluster were assigned to their source species. For assessing the occurrence of BIRC6-like proteins in different taxa, the presence of an E2-like domain including the C-terminal extension and an extensive N-terminal region with BIR repeats was scored by generalized profiles<sup>71</sup>.

### Cryo-EM sample preparation

**UBA6–BIRC6<sup>UBC</sup> sample.** The noncovalent UBA6–BIRC6<sup>UBC</sup> complex was generated during optimization of the UbDha-trapped samples using a probe batch with reduced activity. Proteins were mixed at the concentrations described above and the complex was purified by SEC (Superdex 200, Cytiva). Fractions containing both UBA6 and BIRC6<sup>UBC</sup> were pooled and concentrated to approximately 50  $\mu\text{M}$  (8  $\text{mg ml}^{-1}$ ).

### UBA6–UbDha–BIRC6<sup>UBC</sup> and dUBA1–UbDha–dBIRC6<sup>UBC</sup> samples.

E1–E2 trapped ternary complex formation was performed as described above and purified by SEC (Superdex 200, Cytiva). Fractions containing E1–UbDha–E2 complexes were pooled and concentrated to approximately 50  $\mu\text{M}$  (8  $\text{mg ml}^{-1}$ ).

To resolve preferred orientation observed in initial screening trials, all cryo-EM samples were supplemented with 0.01% (w/v) fluorinated octyl maltoside immediately before vitrification. Vitrification in liquid ethane was performed using an automated plunge-freezing device (Vitrobot IV, Thermo Fisher Scientific) operated at 6  $^{\circ}\text{C}$  and 100% humidity with a blot time of 7 s.

### Cryo-EM data collection

Preliminary grid screening was performed on a Talos Arctica microscope (Thermo Fisher Scientific, Central Oxford Structural Molecular Imaging Center (COSMIC) facility) to assess sample quality. High-resolution datasets were collected on Titan Krios G3 instruments (Thermo Fisher Scientific; Electron Bio-Imaging Center (eBIC): UBA6–BIRC6<sup>UBC</sup> and COSMIC: UBA6–UbDha–BIRC6<sup>UBC</sup> and dUBA1–UbDha–dBIRC6<sup>UBC</sup> samples) with Gatan BioQuantum image filters

(20-eV slit width) and Gatan K3 direct electron detectors. Additional data collection parameters are described in Tables 1 and 2.

### Cryo-EM data processing

Preprocessing (MotionCor2 (ref. 73), CTFFind4 (ref. 74) and cryOLO<sup>75</sup> particle picking) for the UBA6–BIRC6<sup>UBC</sup> dataset was performed using the PATO on-the-fly processing interface available at eBIC<sup>76</sup>. Downstream processing was conducted in cryoSPARC (version 4.4)<sup>77</sup>. The particles were cleaned by two rounds of two-dimensional (2D) classification, yielding a stack of 1,009,462 particles. Ab initio model generation and heterogeneous refinement followed by 3D classification were then used to identify three states within the dataset (UBA6<sup>APO</sup>, UBA6–BIRC6<sup>UBC-IN</sup> and UBA6–BIRC6<sup>UBC-OUT</sup>) and classify particles among them while further removing junk particles (253,166, 136,457 and 139,520 particles respectively). These classes were then refined independently using nonuniform refinement<sup>78</sup> to produce consensus maps. Heterogeneity within the UBA6<sup>APO</sup> and UBA6–BIRC6<sup>UBC-OUT</sup> classes was then analyzed with 3DVA<sup>79</sup> and particles clustered at either end of the first principal component for each class were refined to produce the final 3DVA cluster maps.

Preprocessing (motion correction, contrast transfer function (CTF) estimation and template picking) for the UBA6–Ubdha–BIRC6<sup>UBC</sup> and dUBA1–Ubdha–dBIRC6<sup>UBC</sup> datasets was performed in SIMPLE (version 3.3.0)<sup>80</sup>. Templates for picking were derived from low-resolution maps from initial grid screening. Particles for both datasets were then cleaned in cryoSPARC (version 4.4)<sup>77</sup> using 2D classification and heterogeneous refinement. The UBA6–Ubdha–BIRC6<sup>UBC</sup> complex was found both singly and doubly loaded with ubiquitin (170,986 and 206,823 particles respectively). The singly loaded state was refined directly in cryoSPARC (version 4.4) to produce a consensus map without further processing. The doubly loaded state was exported to RELION (version 5.0), further cleaned by 3D classification and subjected to Bayesian polishing and CTF refinement<sup>81</sup> before a final nonuniform refinement<sup>78</sup> in cryoSPARC (version 4.4). The dUBA1–Ubdha–dBIRC6<sup>UBC</sup> complex was only found in the doubly loaded state. Particles for this class were exported to RELION (version 5.0) for polishing and CTF refinement<sup>81</sup> and finally refined in cryoSPARC (version 4.4). Flexibility of the transferred ubiquitin within particles of both doubly loaded complexes was then analyzed with 3DVA<sup>79</sup> and clustering along principal components was used to isolate subsets of particles with improved ubiquitin density.

### Model building and refinement

Initial models for all proteins were produced in AlphaFold2 (ref. 82), except for ubiquitin adenylate, which was derived from PDB 9B5C (ref. 36). Models were initially refined using ISOLDE<sup>83</sup>, followed by multiple rounds of real-space refinement in PHENIX (version 1.21.2)<sup>84</sup> and manual editing in Coot (version 0.9.8.92)<sup>85</sup>.

### E1–E2 transthiolation assays

E1–E2 transthiolation assays were performed at concentrations of 0.5  $\mu$ M E1, 3  $\mu$ M E2, 5  $\mu$ M ubiquitin and 10 mM ATP in buffer containing 40 mM HEPES pH 7.3, 10 mM MgCl<sub>2</sub> and 0.6 mM DTT. All reactions were stopped at indicated time points after addition of ATP by mixing 1:1 with nonreducing SDS sample buffer. Samples were then analyzed by SDS–PAGE and Coomassie staining. Band quantification was performed within each lane to measure the proportion of E2–Ub thioester relative to unloaded E2 using ImageJ<sup>86</sup>. Subsequent data analysis and plotting were performed in R (version 4.4.0).

Single-turnover time-course transthiolation assays were performed with reagents at the concentrations described above. E1 was first loaded with ubiquitin for 15 min at room temperature, followed by addition of EDTA to a final concentration of 50 mM and incubation for 5 min at room temperature to prevent further ubiquitin adenylation. E2s were then added (3  $\mu$ M UBE2D2 alone or 3  $\mu$ M UBE2D2 + 3  $\mu$ M competitor) and samples were taken at the indicated time points.

Multiple-turnover time-course assays were performed at concentrations as described above. ATP was first added to E1 and ubiquitin and incubated at room temperature for 15 min to allow for initial E1 loading. E2 was then added and samples taken at the indicated time points.

E2 competition assays were performed as described above with the addition of a competitor E2 at the following concentrations: 0.75, 1.5, 3.0, 4.5 and 6.0  $\mu$ M, which was mixed with the other reagents before the addition of ATP. BIRC6–C4666A (3.0  $\mu$ M) was used as a competitor against the panel of all UBA6-active E2s. When catalytically active competitor E2s were used, the ubiquitin concentration in the reaction was increased to 10  $\mu$ M to ensure molar excess of the substrate.

### Analytical SEC

For assessment of stable complex formation of UBA6–BIRC6<sup>UBC</sup>, UBA1–BIRC6<sup>UBC</sup>, UBA6–UBE2D2, UBA6–UBE2Z, UBA1–dBIRC6<sup>UBC</sup> and UBA6–dBIRC6<sup>UBC</sup> proteins were combined in 20 mM HEPES pH 7.5, 200 mM NaCl and 4 mM DTT each at 10  $\mu$ M in 100  $\mu$ l and applied to a Superdex 200 Increase 3.2/300 column (Cytiva). For analysis of the dUBA1–dBIRC6<sup>UBC</sup> interaction, proteins were diluted to 5  $\mu$ M in the same buffer and 500  $\mu$ l of sample was applied to a Superdex 200 10/300 column. Identical fractions from each run were mixed with SDS sample buffer and analyzed by SDS–PAGE and Coomassie staining.

### ITC

ITC measurements were performed in 20 mM HEPES pH 7.5, 200 mM NaCl and 2 mM TCEP using an Auto-iTC200 instrument (Malvern Panalytical) at 25 °C. Then, 1 mM UBA6<sup>UFD</sup> in the syringe was titrated against BIRC6<sup>UBC</sup> variants at 70  $\mu$ M in the calorimeter cell using 19 injections of 2  $\mu$ l preceded by a 0.4- $\mu$ l injection. The changes in heat release were integrated over the entire titration and fitted to a single-site binding model using the PEAQ analysis software (Malvern Panalytical). Graphs were plotted in GraphPad Prism 9.

### Fluorescence polarization

Cy5-labeled BIRC6<sup>UBC</sup> variants in 20 mM HEPES pH 7.8, 200 mM NaCl and 2 mM DTT were incubated with an eightfold molar excess of Cy5 *N*-hydroxysuccinimide ester (Lumiprobe) at room temperature for 2 h. The reaction was quenched with 1 M Tris pH 8.5 and Cy5-labeled proteins were separated from unreacted Cy5 by SEC (Superdex 75, Cytiva). To generate stable ubiquitin-loaded BIRC6<sup>UBC</sup>, a modified strategy for forming the trapped ternary complex was used. Briefly, 10  $\mu$ M Cy5-labeled BIRC6<sup>UBC</sup> was mixed with 4  $\mu$ M UBA6, 40  $\mu$ M Ubdha and 10 mM ATP in buffer containing 40 mM HEPES pH 7.3, 10 mM MgCl<sub>2</sub> and 0.6 mM DTT and then incubated at room temperature for 2 h. To collapse the Ubdha–UBA6 thioester bond, 50 mM DTT was added. Ubdha-reacted and nonreacted BIRC6<sup>UBC</sup> were separated by anion-exchange chromatography (Mono Q, Cytiva) in 20 mM Tris pH 8.5, 20 mM NaCl and 2 mM DTT and eluted with a shallow gradient of anion-exchange buffer containing 1 M NaCl. BIRC6<sup>UBC</sup>–Ub was concentrated, flash-frozen in single-use aliquots and stored at –75 °C before use.

Fluorescence polarization assays were performed on a Clariostar plate reader (BMG Labtech) using 635 nm (20) and 680 nm (20) excitation and emission channels, respectively. Serial dilutions of UBA6 variants were prepared in fluorescence polarization buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM DTT, 0.05% (w/v) CHAPS and 0.04 mg ml<sup>–1</sup> BSA) and pipetted into a 384-well black low-binding plate (Corning) containing a final concentration of 15 nM Cy5-labeled BIRC6<sup>UBC</sup> variants. Data were plotted and fitted in GraphPad Prism 9.

### Detection of UBA6–BIRC6 complex in cellulo

Catalytically active and inactive UBA6 variants (full-length,  $\Delta$ Cys–Cap loop and UBA6–1UFD) were cloned into a modified pcDNA5 vector containing an N-terminal Twin–Strep–eGFP–3C tag. HEK293T cells (American Type Culture Collection, CRL–3216) were cultured in DMEM

(Sigma, D6429) + 10% FBS at 37 °C in 5% CO<sub>2</sub>. For each UBA6 construct ~700,000 cells were seeded in one 10 cm dish for transfection 24 h later with 0.25–7.5 µg of pcDNA 5 StrepII–GFP–UBA6 constructs to obtain similar expression levels of each variant. PEI was used as the transfection reagent at threefold excess to DNA. Cells were harvested 24 h after transfection and resuspended in 1 ml of lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.2% IGEPAL CA-630 (Sigma) and 1 mM DTT, supplemented with cOmplete protease inhibitors (Roche), 1 µM pepstatin and 2 µM leupeptin) followed by gentle microsonication of two 1 s pulses. Lysates were clarified by two successive rounds of centrifugation at 21,000g for 15 min at 4 °C. Lysate concentrations were determined by Bradford (BioRad). StrepII–GFP–UBA6 variant complexes were enriched by applying 4 mg of each clarified lysate to Strep-Tactin XT 4-Flow resin (IBA) for 1 h at 4 °C with end-over-end rotation. Nonbound proteins were removed through six washes in 50 mM Tris pH 7.5, 150 mM NaCl and 1 mM DTT. Proteins were eluted in Laemmli SDS sample buffer. For western blot analysis, 1% of each lysate input was analyzed; for eluted complexes, amounts analyzed were normalized on the basis of GFP quantification (iBright 1500, Thermo Fisher) of resin after a final wash before elution. Samples were analyzed on NuPAGE 3–8% Tris–acetate gel (Thermo Fisher) run in NuPAGE Tris–acetate SDS running buffer (Thermo Fisher) and transferred to PVDF membrane overnight, 4 °C in NuPAGE transfer buffer (Thermo Fisher). The membrane was blocked in 5% milk (w/v) in PBST (PBS and 0.1% Tween-20 (v/v)) followed by incubation overnight at 4 °C with the following primary antibodies diluted in 2% (w/v) BSA in PBST: BIRC6 (BD Biosciences, 611193; 1:500), GFP (Merck, 11814460001; 1:2,500) and β-actin (Cell Signaling Technology, 4970S; 1:2,500). Primary antibodies were detected by goat anti-mouse (Agilent) and goat anti-rabbit (BioRad) horseradish peroxidase secondary antibodies at 1:10,000 in 1% milk (w/v) in PBST. The membrane was developed using SuperSignal West Femto substrate (Thermo Fisher) and imaged on an iBright 1500 (Thermo Fisher).

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

Cryo-EM maps were deposited to the EM Data Bank under accession numbers EMD-53130, EMD-53131, EMD-53147, EMD-53149, EMD-53155, EMD-53170, EMD-53183, EMD-53184, EMD-53187, EMD-53188, EMD-53190, EMD-53192, EMD-53193 and EMD-53195. Atomic coordinates were deposited to the PDB under accession numbers 9QH5, 9QHI, 9QIA, 9QGW, 9QGG, 9QGI, 9QGR, 9QIC, 9QIG, 9QII, 9QIV, 9QIM, 9QIO and 9QIP. Source data are provided with this paper.

### References

69. Michel, M. A., Komander, D. & Elliott, P. R. Enzymatic assembly of ubiquitin chains. *Methods Mol. Biol.* **1844**, 73–84 (2018).
70. Perez, M. F. & Sarkies, P. Histone methyltransferase activity affects metabolism in human cells independently of transcriptional regulation. *PLoS Biol.* **21**, e3002354 (2023).
71. Bucher, P., Karplus, K., Moeri, N. & Hofmann, K. A flexible motif search technique based on generalized profiles. *Comput. Chem.* **20**, 3–23 (1996).
72. Frickey, T. & Lupas, A. CLANS: a Java application for visualizing protein families based on pairwise similarity. *Bioinformatics* **20**, 3702–3704 (2004).
73. Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat. Methods* **14**, 331–332 (2017).
74. Rohou, A. & Grigorieff, N. CTFIND4: fast and accurate defocus estimation from electron micrographs. *J. Struct. Biol.* **192**, 216–221 (2015).

75. Wagner, T., et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. *Commun. Biol.* **2**, 218 (2019).
76. Horstmann, A. et al. A service-based approach to cryoEM facility processing pipelines at eBIC. *Acta Crystallogr. D Struct. Biol.* **80**, 174–180 (2024).
77. Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat. Methods* **14**, 290–296 (2017).
78. Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. *Nat. Methods* **17**, 1214–1221 (2020).
79. Punjani, A. & Fleet, D. J. 3D variability analysis: resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM. *J. Struct. Biol.* **213**, 107702 (2021).
80. Caesar, J. et al. SIMPLE 3.0. Stream single-particle cryo-EM analysis in real time. *J. Struct. Biol. X* **4**, 100040 (2020).
81. Zivanov, J., Nakane, T. & Scheres, S. H. W. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. *IUCr* **7**, 253–267 (2020).
82. Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583–589 (2021).
83. Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. *Acta Crystallogr. D Struct. Biol.* **74**, 519–530 (2018).
84. Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. *Acta Crystallogr. D Struct. Biol.* **75**, 861–877 (2019).
85. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501 (2010).
86. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **9**, 671–675 (2012).
87. Nomura, K. et al. Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity. *Nat. Struct. Mol. Biol.* **24**, 578–587 (2017).
88. Kamadurai, H. B. et al. Insights into ubiquitin transfer cascades from a structure of a UbcH5B~ubiquitin–HECTNEDD4L complex. *Mol. Cell* **36**, 1095–1102 (2009).
89. Middleton, A. J., Zhu, J. & Day, C. L. The RING domain of RING finger 12 efficiently builds degradative ubiquitin chains. *J. Mol. Biol.* **432**, 3790–3801 (2020).
90. Lechtenberg, B. C. et al. Structure of a HOIP/E2-ubiquitin complex reveals RBR E3 ligase mechanism and regulation. *Nature* **529**, 546–550 (2016).
91. Yuan, L., Lv, Z., Atkison, J. H. & Olsen, S. K. Structural insights into the mechanism and E2 specificity of the RBR E3 ubiquitin ligase HHARI. *Nat. Commun.* **8**, 211 (2017).
92. Zhang, W. et al. System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes. *Mol. Cell* **62**, 121–136 (2016).

### Acknowledgements

We are grateful for the support from the P.R.E. laboratory, including T. Western. EM provision was provided by the eBIC (proposal BI28731) and COSMIC EM facilities. In particular, we would like to acknowledge R. Matadeen, T. Matthews-Palmer, J. Caesar and E. Lowe for help and support in cryo-EM data collection and processing. We thank T. Clausen (Research Institute of Molecular Pathology Vienna) for a UBE2O expression plasmid. This research was supported by the UK Research Institute Biotechnology and Biological Sciences Research Council (BB/Y008936/1) and Cancer Research UK (DRCPPA-Jun24/100003) awarded to P.R.E.

### Author contributions

P.R.E. designed and initiated the study. C.R. performed the cryo-EM sample preparation, data collection and analysis. C.R., C.J.E., J.W.A. and P.R.E. produced the recombinant enzymes. C.R. performed the biochemical experiments. C.J.E. performed the biochemical experiments and cellular studies. P.S. and K.H. performed the RNAseq and phylogenetic analyses, respectively. C.R., C.J.E. and P.R.E. wrote the manuscript with input from all authors.

### Competing interests

The authors declare no competing interests.

### Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41594-025-01717-z>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41594-025-01717-z>.

**Correspondence and requests for materials** should be addressed to Paul R. Elliott.

**Peer review information** *Nature Structural & Molecular Biology* thanks Marcin Suskiewicz, Helen Walden and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available. Primary Handling Editor: Dimitris Typas, in collaboration with the *Nature Structural & Molecular Biology* team.


**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).



Extended Data Fig. 1 | See next page for caption.


**Extended Data Fig. 1 | Catalogue of E1 domain specificity across the human ubiquitin E2 proteins.** **a**, Schematic of the conserved E1 enzyme domain architecture. **b**, Representative gel displaying *in vitro* E2-Ub thioester formation of a complete panel of recombinantly purified ubiquitin E2 enzymes in the presence of WT UBA1/UBA6. Full-length BIRC6 and UBE2O were used at a lower concentration (1  $\mu$ M vs 3  $\mu$ M) compared to other E2s in the panel. Due to significantly lower transthiolation activity, reactions with UBE2K were stopped after 30 min rather than 5 min (all other E2s). **c**, Cartoons and domain boundaries of chimeric E1 constructs. **d**, Classification of E1 domain specificity requirements across all ubiquitin E2 enzymes. E2s were classified through observation of

robust E2-Ub thioester formation in the presence of chimeric E1 constructs. Due to difficulty separating loaded and unloaded full-length BIRC6 by SDS-PAGE, BDP-labelled ubiquitin was used. Gels are representative of three independent experiments. BIRC6<sup>UBC</sup> was used for the quantification of BIRC6 activity with UBA1/UBA6 in Fig. 1c. **e-f**, Spearman's Rank Correlation coefficients for pairwise combinations of ubiquitin ligases across tissues in the GTEX database. Correlations that were not significant ( $p > 0.01$ ) after multiple test corrections are shown as 0. **e**, All E2s with UBA1 and UBA6 and **f**, shows a restricted set of UBA6-active E2s.



**Extended Data Fig. 2 | Data processing workflow and validation for the UBA6-BIRC6<sup>UBC</sup> cryo-EM dataset. a**, Preprocessing, classification and refinement steps used to generate consensus maps for UBA6<sup>APO</sup>, UBA6-BIRC6<sup>UBC-IN</sup> and UBA6-BIRC6<sup>UBC-OUT</sup> states. **b**, Representative micrograph. **c**, Representative 2D classes


for particles used in each consensus map. **d**, Particle orientation distribution diagram, local resolution map, GSFSC and model-map FSC curves for each consensus map.



Extended Data Fig. 3 | See next page for caption.

**Extended Data Fig. 3 | Representative densities and 3D variability clustering for UBA6-BIRC6<sup>UBC</sup> cryo-EM dataset.** **a**, Cryo-EM density and associated atomic model for selected regions in the UBA6 core (residues 388-406), UBA6 SCCH domain (residues 634-662), BIRC6 helix 1 (residues 4572-4588), UBA6 Cys-Cap loop (residues 799-818) and ATP. **b**, 3D variability analysis and clustering of particles in UBA6<sup>APO</sup> and UBA6-BIRC6<sup>UBC-OUT</sup> consensus maps. Clusters at either end of the first principal component were refined to demonstrate the full range of motion. **c**, Particle orientation plot, local resolution map, GSFSC and model-map FSC curves for each cryo-EM map from 3D variability clustering. **d**, Structural alignment of the UBA6 UFD bound to BIRC6<sup>UBC</sup> in the UBA6-BIRC6<sup>UBC-IN/OUT</sup> states.

The UBA6-BIRC6<sup>UBC-OUT</sup> model is coloured by the C $\alpha$  RMSD. **e**, Measurement of UFD and SCCH movements between clusters 2 and 3 within the UBA6<sup>APO</sup> consensus particle stack. Cluster 3 represents a more closed state, with the UFD and SCCH rotating in by 14° and 6° respectively, narrowing the central E2-binding cavity by 8 Å. **f**, Measurement of UFD-BIRC6<sup>UBC</sup> movements between clusters 0 and 4 within the UBA6-BIRC6<sup>UBC-OUT</sup> consensus particle stack. While bound to UBA6<sup>UFD</sup>, BIRC6<sup>UBC-OUT</sup> can shift up to 16 Å across UBA6<sup>SCCH</sup>, accompanied by a 9° rotation of UBA6<sup>UFD</sup>. **g**, Structural alignment of the UBA6 UFD bound to BIRC6<sup>UBC</sup> in the UBA6-BIRC6<sup>UBC-OUT</sup> cluster 0 and cluster 4 models. The UBA6-BIRC6<sup>UBC-OUT</sup> cluster 4 model is coloured by the C $\alpha$  RMSD.




Extended Data Fig. 4 | See next page for caption.

**Extended Data Fig. 4 | Structural understanding of BIRC6 priority for UBA6 provides a molecular framework for altering E2 specificity whilst not disrupting predicted E2-E3 interactions.** **a**, Supplement to Fig. 2h.

BIRC6<sup>UBC</sup>-Ub, UBE2Z-Ub and BIRC6<sup>UBC</sup> A4575D-Ub thioester formation during single turnover reactions with UBA6 using BDP-labelled ubiquitin, analysed by SDS-PAGE. **b**, Fluorescence image of single turnover transthiolation of E2s (UBE2D2, UBE2D2 and full-length BIRC6, full-length BIRC6) by UBA6. **c**, SDS-PAGE analysis of multiple turnover transthiolation for every UBA6-reactive E2 in the presence of BIRC6<sup>UBC</sup> C4666A using BDP-labelled ubiquitin. **d**, SDS-PAGE analysis of multiple turnover transthiolation of BIRC6<sup>UBC</sup> and BIRC6<sup>UBC</sup> A4575D. **e**, Model of UBE2D2 annotated to demonstrate the core UBC domain architecture. **f-h**, SDS-PAGE analysis of E2-Ub thioester formation for WT and mutant E2s (**f**, UBE2H, UBE2W, UBE2E1; **g**, UBE2D2; **h**, UBE2Q1, UBE2Q2) with UBA1/UBA6, visualised using BDP-labelled ubiquitin. Specific amino acid mutations or domain truncations are annotated beneath each gel panel. **i**, View of BIRC6 'helix 1' residues interacting with UBA6 UFD. **j-o**, Representation of


the interaction between UBE2D2 and UBE2L3 helix 1 and selected E3 ligases. Representative members of the different families of E3 ligases were chosen. For each E2-E3 complex, residues from helix 1 that engage with the E1 are shown, and these are located on the opposite face from those that bind to the E3. **j**, UBE2D2 in complex with MDM2 RING domain. PDB id: 5MNJ<sup>87</sup>. **k**, UBE2D2 in complex with Nedd4 HECT domain. PDB id: 3JW0<sup>88</sup>. **l**, UBE2D2 in complex with RNF12 RING domain. PDB id: 6W9D<sup>89</sup>. **m**, UBE2D2 in complex with HOIP RBR domain. PDB id: 5DEV<sup>90</sup>. **n**, UBE2L3 in complex with ARIH1 RBR domain. PDB id: 5TTE<sup>91</sup>. **o**, UBE2L3 in complex with WWP1 HECT domain. PDB id: 5HPT<sup>92</sup>. **p**, Helical wheel projection of helix 1 from UBE2D2 depicting positions of residues that interact with either E1 or E3 structural elements. Residues outlined in the orange box are those that were mutated in this study that prevent association with UBA6; these are at equivalent positions to sites mutated in the UBA1-specific E2s (UBE2H, UBE2W, UBE2E1) that enabled activity with UBA6. Gel images are representative of three independent experiments.



Extended Data Fig. 5 | See next page for caption.


**Extended Data Fig. 5 | Analysis of dBIRC6<sup>UBC</sup> interactions with E1 enzymes and purification of E1-UbDha-E2 complexes for cryo-EM.** **a-c**, Analytical SEC of dBIRC6<sup>UBC</sup> with the *Drosophila* (**a**, dUBA1) and human (**b**, UBA1; **c**, UBA6) E1 enzymes. SDS-PAGE gel analysis of fractions across the E1 and E2 peaks are shown. **d**, Generation of the UbDha probe and reaction mechanism with UBA6 C625S. After adenylation, the UBA6 nucleophile (O<sup>-</sup>) can react with either the Dha sidechain to form a non-reactive E1-UbDha adduct (1), or the C-terminal carboxyl group of UbDha (2). Following pathway (2), in the presence of E2 a second

reaction can occur, where the E2 nucleophile (S<sup>-</sup>) may again attack at either the Dha sidechain (3), or the oxy-ester linkage (4). Reactions 2, 3 produce the trapped E1-UbDha-E2 ternary complex. **e**, Preparation of the dUBA1-UbDha-dBIRC6<sup>UBC</sup> cryo-EM sample. Left - size exclusion chromatography trace for sample purification. Right - SDS-PAGE analysis of sample following sample preparation (-/+ ATP) and purification by size exclusion chromatography (P1-3). **f**, SDS-PAGE gel showing the equivalent P1 sample from size exclusion chromatography of the UBA6-UbDha-BIRC6<sup>UBC</sup> complex.



**Extended Data Fig. 6 | Data processing workflow and validation for the UBA6-UbDha-BIRC6<sup>UBC</sup> cryo-EM dataset. a**, Preprocessing, classification and refinement steps used to generate consensus maps for UBA6-UbDha-BIRC6<sup>UBC</sup> singly and doubly loaded states. **b**, Representative micrograph. **c**, Representative


2D classes for particles used in each consensus map. **d**, Particle orientation distribution diagram, local resolution map, GSFSC and model-map FSC curves for each consensus map.




**Extended Data Fig. 7 | Data processing workflow and validation for the dUBA1-UbDha-dBIRC6<sup>UBC</sup> cryo-EM dataset. a**, Preprocessing, classification and refinement steps used to generate the consensus map for doubly loaded dUBA1-UbDha-dBIRC6<sup>UBC</sup>. **b**, Representative micrograph. **c**, Representative

2D classes for particles used in the consensus map. **d**, Particle orientation distribution diagram, local resolution map, GSFSC and model-map FSC curves for the consensus map.


a



b




c



### Extended Data Fig. 8 | Representative densities and 3D variability clustering for UBA6-UbDha-BIRC6<sup>UBC</sup> and dUBA1-UbDha-dBIRC6<sup>UBC</sup> cryo-EM datasets.

**a**, Cryo-EM density and associated atomic model for selected regions in the E1 core (UBA6 residues 388-406/ dUBA1 residues 533-553), SCCH domain (UBA6 residues 634-662/ dUBA1 residues 776-803), E2 helix 1 (BIRC6 residues 4572-4588/ dBIRC6 residues 4631-4647), and ATP/Ub-AMP. **b**, 3D variability


analysis and clustering of particles in the consensus maps of doubly loaded UBA6-UbDha-BIRC6<sup>UBC</sup> and dUBA1-UbDha-dBIRC6<sup>UBC</sup>. Clusters at either end of the first principal component were refined to demonstrate the full range of motion. **c**, Particle orientation plot, local resolution map, GSFSC and model-map FSC curves for each map from 3D variability clustering.



**Extended Data Fig. 9 | Analysis of the E1-UbDha-BIRC6<sup>UBC</sup> structures.**

**a**, Close-up views of the E1-UbDha-E2 linked densities and atomic models for UBA6-UbDha-BIRC6<sup>UBC</sup> (left) and dUBA1-UbDha-dBIRC6<sup>UBC</sup> (right) consensus maps. **b**, Cryo-EM maps of particle subsets generated through 3D variability analysis and clustering of the UBA6-UbDha-BIRC6<sup>UBC</sup> and dUBA16-UbDha-dBIRC6<sup>UBC</sup> particle stacks. The distance between Ub<sup>Tran</sup> centre of mass between each pair of maps is annotated. **c**, Close-up views of UBA6<sup>UFD</sup>-BIRC6<sup>UBC</sup> (top, Consensus model), BIRC6<sup>UBC</sup>-Ub<sup>Tran</sup> (middle, 3DVA Cluster 0 model) and UBA6<sup>SCCH</sup>-BIRC6<sup>UBC</sup> (bottom, Consensus model) interfaces. **d**, Quantification

from three independent technical replicates of E2-Ub thioester formation (mean ± s.d.) of BIRC6<sup>UBC</sup> mutants validating interactions at UBA6<sup>UFD</sup> (top), Ub<sup>Tran</sup> (middle) and UBA6<sup>SCCH</sup> (bottom) interfaces. Because Ub<sup>Tran</sup> and UBA6<sup>SCCH</sup> mutant panels were performed on the same gel, the same WT control measurements are shared for both panels. **e**, Quantification from three independent technical replicates of E2-Ub thioester formation (mean ± s.d.) by UBA6 mutants with BIRC6<sup>UBC</sup>, UBE2Z and UBE2D2. Significance levels from unpaired t-tests of all quantification comparisons (**d, e**): \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001.



**Extended Data Fig. 10 | Analysis of the Human and *Drosophila* E1-UbDha-BIRC6<sup>UBC</sup> structures.** **a**, Structural alignment of BIRC6<sup>UBC</sup> and dBIRC6<sup>UBC</sup> in the trapped ternary complex models. The BIRC6<sup>UBC</sup> model is coloured by the C $\alpha$  RMSD. **b**, Comparison of the UBA6-UbDha-BIRC6<sup>UBC</sup> and dUBA1-UbDha-dBIRC6<sup>UBC</sup> consensus models, aligned on the E1 core. The shift in centre of mass between Human and *Drosophila* BIRC6 bound to their respective E1s is annotated. **c**, Top view of h/dBIRC6<sup>UBC</sup> bound to their cognate E1s, aligned on the E1 core. The *Drosophila* BIRC6 C-terminal helices are shifted ~5 Å relative to the equivalent

helices in Human BIRC6 to accommodate the dUBA1<sup>SCCH</sup>. **d**, Summary of chimeric Human and *Drosophila* BIRC6<sup>UBC</sup> constructs used in Fig. 4h. **e**, Alignment of Human and *Drosophila* BIRC6<sup>UBC</sup> sequences. Boundaries/point mutations used for generating chimeric constructs are annotated according to the key below. BIRC6 residues within 5 Å of their cognate E1 in the trapped ternary complex structures are annotated with blue (Human proteins) or pink (*Drosophila* proteins) marks. Residues are coloured based on their properties defined by the Clustal colouring scheme. **f**, Alignment of Human and *Drosophila* UBA1 UFDS.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- |                                     |                                     |  |
|-------------------------------------|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            | A description of all covariates tested   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated   |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection Gel imaging: iBright (Invitrogen); Cryo-EM: FEI (EPU), Malvern Panalytical.

Data analysis Malvern Panalytical, GraphPad Prism v10.3.1.; Cryo-EM: EPU\_TO\_AFIS, RELION 5.0, cryoSPARC v4.4, SIMPLE v3.3.0, CTFFind4, MotionCor2 ; Structure Visualization: ChimeraX 1.9, PyMol 2.5.2; Model Building: ISOLDE, COOT v0.9.8.92, PHENIX 1.21.1, ColabFold notebook

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

EMD-53184, EMD-53187, EMD-53188, EMD-53195, EMD-53190, EMD-53192, EMD-53193, EMD-53155, EMD-53170, EMD-53183, EMD-53149, EMD-53130, EMD-53131, EMD-53147, 9QIC, 9QIG, 9QII, 9QIV, 9QIM, 9QIO, 9QIP, 9QH5, 9QHI, 9QIA, 9QGW, 9QGG, 9QGI, 9QGR

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	n.a.
Reporting on race, ethnicity, or other socially relevant groupings	n.a.
Population characteristics	n.a.
Recruitment	n.a.
Ethics oversight	n.a.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	All experiments were performed at least three times.
Data exclusions	No data was excluded.
Replication	All experiments were performed at least three times. All replicates were successful.
Randomization	No grouped samples.
Blinding	No grouped samples.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

Antibodies used	BIRC6 (BRUCE) - BD Biosciences cat. no. 611193, clone no. 4/BRUCE. GFP - Merck cat. no. 11814460001, clones 7.1 and 13.1. b-actin - Cell Signaling Technology cat. no. 4970S, clone 13E5. Goat anti-mouse (HRP) - Agilent Cat. no. P044701-2
-----------------	---

Goat anti-rabbit (HRP) - BioRad Cat. no. 1706515

## Validation

Validation performed by manufacturer of respective antibodies:

BIRC6 - ([www.bdbiosciences.com/en-us/products/reagents/microscopy-imaging-reagents/immunofluorescence-reagents/purified-mouse-anti-bruce.611193?tab=product\\_details](http://www.bdbiosciences.com/en-us/products/reagents/microscopy-imaging-reagents/immunofluorescence-reagents/purified-mouse-anti-bruce.611193?tab=product_details))GFP - ([www.sigmaaldrich.com/GB/en/product/roche/11814460001?srsId=AfmBOor53lyPhN8NDIC62zvKmtKj5eG3e55cxLkylurkrjr2Lqns1plb](http://www.sigmaaldrich.com/GB/en/product/roche/11814460001?srsId=AfmBOor53lyPhN8NDIC62zvKmtKj5eG3e55cxLkylurkrjr2Lqns1plb))b-actin - ([www.cellsignal.com/products/primary-antibodies/b-actin-13e5-rabbit-mab/4970](http://www.cellsignal.com/products/primary-antibodies/b-actin-13e5-rabbit-mab/4970))Goat anti-mouse (HRP)- ([www.agilent.com/store/productDetail.jsp?catalogId=P044701-2&catId=SubCat3ECS\\_244794](http://www.agilent.com/store/productDetail.jsp?catalogId=P044701-2&catId=SubCat3ECS_244794))Goat anti-rabbit (HRP) - ([www.bio-rad.com/en-uk/sku/1706515-goat-anti-rabbit-igg-h-l-hrp-conjugate?ID=1706515](http://www.bio-rad.com/en-uk/sku/1706515-goat-anti-rabbit-igg-h-l-hrp-conjugate?ID=1706515))

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

Sf9 insect cell line (Spodoptera frugiperda), HEK293T (ATCC no. CRL-3216)

Authentication

no authentication was performed.

Mycoplasma contamination

HEK293T cells were tested and confirmed to be mycoplasma negative.

Commonly misidentified lines  
(See [ICLAC](#) register)

None.

## Plants

Seed stocks

n.a.

Novel plant genotypes

n.a.

Authentication

n.a.